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1 Introduction  
1.1 Preparation of whole blood for clinical-chemical         
LC-MS/MS analysis: State-of-the-art  
 
The combination of High Performance Liquid Chromatography with selective and 
sensitive Tandem Mass Spectrometry (HPLC-MS/MS) has become the technique of 
choice for the analysis of low-molecular weight compounds in biological fluids in 
clinical-chemical and pharmaceutical laboratories. However, complex body fluids, 
such as whole blood, have to be pretreated prior to LC-MS/MS analysis in order to 
deplete the protein matrix and interfering sample components.  
Sample preparation often represents the most laborious and time-consuming step in 
an analytical protocol. It significantly affects the quality, throughput and costs of the 
analysis. Thus, an appropriate sample preparation is the key factor for an accurate, 
reliable and efficient analytical procedure.  
Pretreatment of whole blood involves at least two steps. First, the protein matrix has 
to be depleted, if not removed completely. Second, the resulting preprocessed blood 
sample has to be further cleaned by Solid Phase Extraction (SPE). 
There are different ways to deplete the protein matrix of an anticoagulated blood 
sample [1]. 
 
Membrane filtration of anticoagulated whole blood (cf. Figure 1, A): Depending on the 
pore diameter, i.e. the molecular weight cut-off, either the blood cells or a fraction of 
plasma proteins is retained by the filter and removed. The remaining plasma proteins 
in the filtrate are depleted by precipitation followed by centrifugation. 
Hemolysis of anticoagulated whole blood (cf. Figure 1, A): After dilution of a blood 
sample with distilled water (blood/water, 1/20, v/v) or the addition of a lysis-buffer, the 
erythrocytes depleted from hemoglobin, i.e. the “ghosts”, are removed by 
centrifugation. The protein matrix of the resulting hemolysate is depleted by 
precipitation followed by centrifugation.  
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Preparation of secondary specimens, i.e. plasma or serum (cf. Figure 1, A): After 
centrifugation of an anticoagulated / clotted sample of whole blood, the resulting 
plasma / serum aliquots are precipitated and centrifuged again. 
Precipitation of whole blood (cf. Figure 1, A): The protein matrix is denatured by 
addition of a precipitating agent and removed by centrifugation.  
 
 
Figure 1: Operational procedures for preparation of whole blood: Protein precipitation. 
 
In all four procedures listed in Figure 1, precipitation of the protein matrix takes place. 
Protein precipitation is a simple and commonly used technique to deplete the protein 
matrix of a body fluid and to disrupt protein-drug binding [2]. The relative efficiency of 
different precipitants has been extensively investigated by Blanchard [3]. For whole 
blood, a mixture of MeOH / ZnSO4 0.4 M (80/20, v/v) is often used [4-7], as this 
mixture results in a tight pellet after centrifugation. An appropriate Internal Standard 
(IS) is preferably dissolved in and added with the precipitating agent. The technique 
of protein precipitation has some essential disadvantages. The potential co-
precipitation of analyte(s) impairs the recovery, and the incomplete removal of matrix 
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proteins leads to matrix effects during ESI-MS/MS detection [8,9]. 
 
Another methodological approach, which is currently the most intensively 
investigated technique in the pharmaceutical industry, is the Dried Blood Spot (DBS, 
cf. Figure 2, B) technique. 
 
 
Figure 2: Operational procedures for preparation of whole blood: Dried Blood Spot (DBS). 
 
A defined amount, e.g. 30 µL of native whole blood is carefully pipetted and spotted 
onto a special marked filter paper/card without touching the card with the filter tip. 
After drying at room temperature for at least three hours, such a Dried Blood Spot 
(DBS) is punched, if necessary repeatedly. The target analyte(s) are extracted from 
the corresponding disk(s) by vortexing in the presence of an organic solvent for 60 
min. Finally, only an aliquot of the supernatant is subjected to further clean-up. Thus 
the sample is diluted before the final analysis. Furthermore, the addition of the 
Internal Standard (IS) takes place late, at the extraction step (Figure 3). 
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Figure 3: Preparation of Dried Blood Spot (DBS). 
 
Recently, an alternative procedure with respect to DBS, the preparation of Dried 
Blood Extract (DBE), has been developed in the Laboratory of BioSeparation, 
Institute of Laboratory Medicine, Medical Center of the University of Munich (cf. 
Figure 4, C and Figure 5) [10]. A sample of whole blood is added to a precipitating 
agent (organic solvent with dissolved Internal Standard), contained in a special 
filtration tube which prevents dripping of the agent. Upon low-speed centrifugation, 
the resulting filtrate is directly collected into a HPLC vial and simultaneously 
evaporated to dryness by applying a vacuum. After removing the filtration tube, the 
DBE can be shipped in a closed HPLC vial and then simply reconstituted by addition 
of a solvent prior to SPE-LC-MS/MS analysis. 
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Figure 4: Operational procedures for preparation of whole blood: Dried Blood Extract (DBE). 
 
 
 
Figure 5: Preparation of Dried Blood Extract (DBE). 
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However, all the methods described so far can only be partly automated. This makes 
the preparation of whole blood sample time consuming, error-prone and cost-
intensive.  
 
One step towards total automation has been the introduction of tailor-made SPE 
packing materials and the application of on-line SPE-LC column switching [11,12]. 
These special SPE columns allow a repetitive injection and fractionation of native 
body fluids such as plasma, serum and urine.  
The fractionation into low- and high-molecular weight compounds is based on Size 
Exclusion Chromatography (SEC) or Turbulent Flow Chromatography (TFC). The 
small molecules, i.e. target analytes, are retained on the stationary phase of the SPE 
column, whereas the high-molecular weight components, i.e. proteins, carbohydrates 
and nucleic acids are eluted to waste.  
SPE columns packed with Restricted Access Materials, for example, rely on two-
dimensional chromatography, i.e. SEC in combination with Reversed Phase (RP) -, 
Ion Exchange (IEX) - or Affinity Chromatography (AC). SPE columns packed with 
conventional porous materials, such as alkyl-bonded phases, and operated at a high 
linear flow velocity rely on Turbulent Flow Chromatography (TFC). Due to the very 
short residence time in the SPE column (size 50 x 0.5 mm ID), macromolecular 
sample components cannot diffuse into the pores and thus are eluted in the void 
volume to waste [13]. Recently, the analytical platform RapidFire was launched by 
Agilent. It consists of a switching valve and a SPE cartridge. The latter is not coupled 
to a LC-column but directly to a MS/MS detector [14].   
The described integrated sample preparation principles, however, cannot be applied 
for whole blood samples, because the blood cells clog the capillaries, sieves and 
SPE columns (cf. Figure 6, D). 
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Figure 6: Operational procedures for preparation of whole blood: Chromatographic clean-up.  
 
In order to enable on-line SPE of an anticoagulated blood sample, two special, 
embedded treatment procedures have been developed in the Laboratory of 
BioSeparation, Institute of Laboratory Medicine, Medical Center of the University of 
Munich [15-17]. Whole blood is treated in-line either by heat-shock treatment for 13 
seconds at 75 °C or by snap-freezing with liquid ni trogen followed by slow thawing. In 
both cases, whole blood is converted into so-called Cell-Disintegrated Blood (CDB). 
The disintegration of blood cells generates subcellular particles which have an 
average diameter of 1 µm. These particles do not sediment on standing and do not 
clog a chromatographic system (cf. Figure 7).  
Thus, anticoagulated whole blood can be directly processed, converted in-line to 
CDB, treated on-line by SPE and finally analyzed by LC-MS/MS in a fully automated 
way (cf. Figure 8, E).  
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Figure 7: Conversion of anticoagulated whole blood (WB) into cell-disintegrated blood (CDB) 
 
 
Figure 8: Operational procedures for preparation of whole blood: In-line processing of whole 
blood and conversion into Cell-Disintegrated Blood (CDB). 
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1.2 Aims of the thesis 
 
The major aims of the thesis were to set-up, program, optimize and evaluate an 
instrumental platform for fully automated SPE-LC-MS/MS analysis of a model analyte 
in whole blood.  
The immunosuppressant Cyclosporine A was chosen as the model analyte, as this 
drug predominantly binds to erythrocytes.  
For the sampling and mixing of anticoagulated whole blood, two novel liquid-handling 
modules and a mixing unit had to be integrated in a XYZ-autosampler, programmed 
and optimized with regard to their mode of operation.  
For in-line processing of whole blood, i.e. its conversion into Cell-Disintegrated Blood 
(CDB), home-made modules for heat-shock treatment and cryogenic treatment had 
to be installed, programmed and optimized with regard to each treatment procedure.  
The embedded, in-line sample processing modules then had to be hyphenated with a 
SPE-unit which had to be operated at high flow rates (Turbulent Flow 
Chromatography).  
Furthermore, in order to set-up a robust analysis system, different in-line filters had to 
be tested and optimized towards a maximum of analysis cycles.  
In the next step, the filter and SPE-unit had to be coupled on-line via switching valves 
to a LC-MS/MS system. In addition, the different wash steps of the filter, columns and 
capillaries had to be optimized to ensure a routine, unattended operation.  
Another goal was to proof the applicability of commercial calibrators and quality 
control samples for the analysis platform. Furthermore, the overall analysis procedure 
had to be validated with respect to linearity, range, sensitivity, accuracy, precision 
and recovery of the model analyte. 
Finally, a method comparison with the routine, semi-automated procedure of the 
Institute of Laboratory Medicine, University of Munich, was performed and 
interpreted. 
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2 Theoretical part 
 
2.1 Whole blood 
 
Whole blood is the main transport medium in the human body, and thus the most 
important biological fluid for clinical-chemical analysis.  
Whole blood represents a two-compartment-system, which is composed of liquid 
blood plasma and blood cells (erythrocytes, leukocytes, thrombocytes and subtypes) 
as shown in Figure 9.  
 
Figure 9: Components of whole blood [18] 
 
About 45 % of whole blood is represented by blood cells, whereby erythrocytes are 
the most abundant cells with more than 95 % of total blood cells.  
Mature erythrocytes are oval, biconcave disks with a size of about 7 µm. They lack a 
cell nucleus and have a fixed period of existence before their components are 
recycled [19]. Erythrocytes are very flexible and can be deformed easily when flowing 
through capillaries [20]. The reddish color of erythrocytes is due to hemoglobin, which 
makes up about 97% of the dry content of erythrocytes [21].  
Leucocytes are divided according to their morphological and functional 
characteristics into monocytes, granulocytes and lymphocytes. Leucocytes have a 
nucleus and are variously shaped.  The number of leucocytes in whole blood is 
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normally 6000 / µL. They play a central role in the immune system. 
Thrombocytes are small, irregularly shaped, enucleated cell fragments, which are 1-
3 µm in diameter [22]. The number of thrombocytes in whole blood is between 
200.000 – 300.000 / µL. One of the primary functions of thrombocytes is to facilitate 
blood clotting.  
The hematocrit is defined as the volume percentage of erythrocytes in whole blood. 
The hematocrit varies depending on sex and environmental conditions, and is 
normally about 45%.  
The liquid component of blood is blood plasma, which is straw-colored. It is prepared 
by centrifugation of anticoagulated blood. Blood plasma consists of more than 90 % 
water, 7-8 % proteins, and other dissolved constituent parts, which are fats, 
enzymes, lipids, hormones, minerals, metabolites and waste products. The 
composition of plasma is shown in Figure 10. Plasma proteins possess a large 
surface area with numerous hydrophilic and lipophilic binding sites for endogenous 
compounds and drugs [23]. Albumin is the most abundant of the plasma proteins. 
 
 
Figure 10: Composition of human blood plasma (according to Geigy Scientific tables) [24]. 
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2.2 On-line Solid Phase Extraction (SPE)  
 
The pretreated samples of whole blood - both the matrix-depleted sample produced 
by established technologies and the matrix containing CDB sample – have to be 
further processed by solid phase extraction (SPE) before an aliquot can be injected 
onto a LC-MS/MS analysis platform.  
 
 
2.2.1 Solid Phase extraction 
 
Due to its simplicity and versatility, SPE is widely used as a clean-up technique in 
instrumental bioanalysis. SPE physically extracts an analyte from a liquid matrix by 
partitioning the solutes between the solid phase (sorbent) of the SPE column and the 
liquid phase in order to isolate and pre-concentrate the analyte(s) [25,26]. The 
analyte(s) of interest is then eluted from the sorbent while interferences either pass 
straight through the sorbent bed or remain adsorbed to it.  
The SPE procedure usually consists of four distinct and consecutive steps [25,27]: 
Column conditioning / equilibration: The sorbent bed must be conditioned with an 
organic solvent of appropriate polarity to promote good surface contact between the 
two phases before the extraction step. This step also includes the equilibration of the 
sorbent bed with a mobile phase that is as similar to the sample as possible, in terms 
of polarity, ionic strength and pH. 
 Adsorption: The liquid sample is percolated through the SPE column at a suitable 
flow rate by application of a gentle pressure or vacuum, which causes the depletion 
of the matrix and the simultaneous enrichment of the analyte(s). The optimal flow rate 
depends on the particle size, the column dimensions and the packing characteristics 
of the sorbent.   
Column washing: The intention of this step is to remove the undesired compounds 
(interference material) from the sorbent as completely as possible without eluting the 
analyte(s).  
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Elution: The adsorbed analyte(s) are eluted from the sorbent using a suitable solvent 
or a mixture of solvents and returned into a liquid phase suitable for analytical 
measurements.  
 
 
2.2.2 On-line SPE-LC via column switching 
 
In on-line SPE, a SPE column is connected to an analytical column via an electrically 
or pneumatically driven six-port valve. The retained analyte(s) is directly eluted from 
the SPE column onto the LC system via a column switching-valve [28].  
The general procedure for column switching consists of three steps. Firstly, the 
pretreated / untreated sample is injected onto the SPE column and fractionated. The 
target analyte is extracted from the sample matrix and retained on the sorbent. 
Concurrently, the interfering sample constituents are flushed into waste. Secondly, 
after rotation of the valve, the retained analyte is eluted on-line onto a series-
connected HPLC column. Thirdly, the analytical separation takes place, and at the 
same time, the SPE column is reconditioned [11,29]. 
In this work, the valve switching time parameters (tA, tM and tT) were determined 
according to Majors et al. [29].  The operational procedure and steps to determine 
valve switching times are documented in 3.2.3.1. 
The hyphenation of SPE with a LC-column via a switching valve is essential for 
automation [25,27]. Automation of SPE for sample preparation is important for many 
reasons. First, it means release from tedious and intensive manual labor and 
therefore a higher sample throughput. The costs involved are also reduced through 
fewer manpower requirements and decreased analysis times. In addition, it reduces 
the exposure of operators to hazardous solvents and infectious samples. 
Furthermore, it improves the analytical quality due to enhanced reproducibility, 
avoidance of human error and the possibility of multiple step elution for cleanup of 
complex samples [26]. Possible disadvantages of such an automation could be 
systematic errors, “carry-over” and matrix-effects due to insufficient fractionation 
[26,30]. These drawbacks can be overcome by optimized wash steps and / or 
multidimensional SPE.   
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2.3 Liquid Chromatography Tandem Mass Spectrometry 
(LC-MS/MS) 
 
After sample clean-up, there is still a need for chromatographic separation of the 
analytes and residual matrix components prior to detection. This is especially true 
when analyzing complex biological samples, such as whole blood. In this work, the 
pretreated sample is separated by High Performance Liquid Chromatography (HPLC) 
prior to the detection by a tandem mass spectrometer (MS/MS).  
A tandem mass spectrometer is capable of ionizing and fragmenting many classes of 
compounds eluting from a LC column. The three principal components of a mass 
spectrometer are: an ion source for formation of gas phase ions which are positively 
or negatively charged, a mass analyzer for separating ions according to their m/z 
ratios and an ion detector for detection of the selected ions.  
The enormous growth of LC-MS/MS is due to the development of atmospheric 
pressure ionization (API) techniques, which enabled LC to be easily and reliably 
interfaced with MS [31,32]. LC-MS/MS offers selective and sensitive detection of 
target analytes, and has played an increasingly important role in clinical laboratories 
during the last 10-15 years [31].  
 
 
2.3.1 Ionization techniques 
 
The API techniques are generally referred to as soft ionization techniques, since the 
predominant ion detected is the quasi-molecular ion rather than other ions resulting 
from fragmentation of the molecule. The three commonly used ionization sources are 
atmospheric pressure chemical ionization (APCI), electrospray ionization (ESI), and 
the recently introduced atmospheric pressure photoionization (APPI) [33-36].  
The suitability of these ionization techniques for the analysis of different compounds 
is often classified by their applicability to analytes with different polarities and 
molecular weights, as shown in Figure 11.  
15 
 
 
Figure 11: Application range of ESI, APCI and APPI ionization techniques for analytes with 
different polarity and molecular weight [37].  
 
It is clear that ESI works best over a broader range of different analytes. 
Furthermore, analytes with a high polarity and a high molecular weight can only be 
analysed by ESI. In this work, ESI was applied for the detection of the target analyte, 
i.e. the immunosuppressant Cyclosporine A.  
The effluent from the LC column enters the ESI source region through the spray 
needle at atmospheric pressure. It is evaporated in a fine mist of droplets facilitated 
by a flow of a neutral gas (e.g. nitrogen) and a high temperature. An electrical field is 
generated by applying a potential difference between the needle and the entrance 
(orifice) of the mass analyzer. The applied electric field leads to the formation of a 
Taylor cone at the needle tip [38]. As the droplet decreases in size by evaporation, 
the electrical charge density at the droplet surface increases up to a critical point, 
known as the Rayleigh stability limit [39]. At this point, the electrostatic repulsion 
between like charges on its surface exceeds the surface tension, and the droplet 
clusters divide into small droplets by Coulombic explosion (Figure 12) [40-42]. This 
process is repeated several times until the sample ions are ejected into the gas 
phase by field desorption. The mechanism of production of the gas phase ions is not 
yet fully understood. According to two proposed theories, the charge residue model 
(CRM) and the ion evaporation mechanism (IEM), the analytes in ESI are ionized in 
solution. The formation of adducts with buffer ions is a common phenomenon in ESI.  
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However, it is possible to increase or decrease the amount of adducts formed by 
altering the mobile phase solvent composition [43,44].  
 
 
Figure 12: A simplified scheme of ion formation in the electrospray ionization (ESI) process, 
operated in positive ion mode [45].  
 
The number of charges retained by an analyte is affected by different factors, such as 
the composition and pH of the electrosprayed solvent, droplet size, liquid surface 
tension, solvent volatility, surface charge and ion solvation strength. For small 
molecules (< 1000 Da), ESI typically generates singly charged ions; for medium 
sized molecules (1000-2000 Da), ESI generates single or double charged ions; and 
for large molecules (> 2000 Da), the ESI process typically gives rise to a series of 
multiply-charged species. Among the common MS techniques, ESI is unique in that 
multiply-charged gas phase ions may be formed, and is suitable for detection of large 
proteins and other biomolecules. A drawback of ESI is its sensitivity to the sample 
matrix [46,47] and dependency on the flow rate. 
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2.3.2 Coupling of LC to ESI-MS 
 
As mentioned previously, the development of atmospheric pressure ionization (API) 
techniques enabled LC to be easily and reliably interfaced with MS [31,32]. 
Generally, the ion formation in ESI mode is most efficient at low flow rate, around 5-
10 µL/min [48]. However, the flow rate can be enhanced up to 1 mL/min through the 
addition of heating capabilities and improvements in the use of drying and nebulizing 
gases [49,50]. A split of the flow to 100-200 µL/min is often recommended [51].  
The choice of solvents used as LC mobile phase affects the formation of ions in 
solution. The composition of the mobile phase must be compatible with the ESI-MS 
detection system and allow chromatographic separation. Sometimes a compromise 
between the sensitivity and the retention may be necessary. The separation 
efficiency of the column is important, even if the MS detector is selective and can 
separate compounds by their mass-to-charge ratios (m/z). Co-eluting peaks may give 
rise to severe suppression of the analyte response. A retention time long enough to 
separate the analyte from interferences, especially early eluting polar matrix 
interferences, is often advantageous. Buffers and pH modifier in the mobile phase 
should be volatile to avoid contamination or plugging of the sample orifice. Operating 
the mass spectrometer with non-volatile buffers, such as phosphate and borate, is 
technically possible, but requires periodic cleaning of the ion source to remove the 
salt deposits. It is recommended to replace nonvolatile buffers with the following 
volatile buffers: formic acid, acetic acid, ammoniac, triethylamine, carbonates, 
ammonium formate, ammonium acetate and ammonium carbonate. The 
concentration of buffer must be kept as low as possible [52]. Ion-pairing agents and 
surfactants should be avoided or added in a very low concentration to avoid ion-
suppression. Furthermore, ESI does not tolerate high salt concentrations or non-polar 
solvents. The trifluoroacetic acid also largely decreases the analyte response [52].  
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2.3.3 Tandem Mass Spectrometry 
 
After ionization, the analyte ions present in the gas phase are directed into a mass 
detection system, which consists mainly of a mass analyzer and a detector.  
In the mass analyzer, the ions are separated according to their m/z ratios.  
Depending on the information required from the ionized analytes, there are several 
types of mass analyzers: quadrupole, ion trap, linear ion trap, orbitrap, magnetic 
sectors, Fourier transform ion cyclotron resonance and time-of-flight [53,54]. 
Hyphenation of different mass analyzers is a trend to increase the versatility and 
allow multiple experiments to be performed [52]. The hybrid instruments, such as 
triple-quadrupole, quadrupole-time-of-flight or quadrupole-ion trap, allow one to 
obtain a mass spectrum resulting from the decomposition of an ion selected in the 
first analyzer [52]. It is possible to fragment over several generations (MSn), where n 
refers to the number of generations of ions being analyzed.  
In the most common tandem mass spectrometry (MS/MS, or MS2), a precursor ion is 
isolated in the first analyzer, and then undergoes a fragmentation to yield product 
ions, which are analyzed in the second analyzer (Figure 13). The fragmentation of 
the precursor ion can be achieved by collisional activation via collisions of selected 
ion with neutral gas molecules (collision-induced dissociation, CID). MS/MS can be 
performed either in space by the coupling of two physically distinct analyzers (e.g. 
triple-quadrupole), or in time by performing an appropriate sequence of events in an 
ion storage device (ion-traps).   
 
 
Figure 13: Principle of tandem mass spectrometry [55].  
 
The four most common MS/MS scan modes are shown in Figure 14. 
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A) Product ion scanning (daughter scanning): A precursor ion (or parent ion) 
of a chosen m/z ratio is selected by MS1 at a certain time, and undergoes 
CID in the collision cell. The resultant product ions (daughter ions) are 
determined by MS2. This process can be repeated for different precursors.  
B) Precursor ion scanning (parent scanning): MS2 is set to transmit a specific 
/ defined fragment ion to the detector. MS1 is scanned to detect all the 
precursor ions that produce this fragment.  
C) Neutral loss scanning: Both analyzers, MS1 and MS2, are scanned in a 
synchronized manner, but with a defined mass offset between the two. For 
a selected neutral fragment, all the fragmentations leading to the loss of 
that neutral are detected. 
D) Multiple ion / reaction monitoring (MRM): It consists of a series of single / 
selected reaction monitoring (SRM), in which MS1 is focused on one 
selected precursor and MS2 on one specific fragment characteristic for that 
precursor. The absence of scanning in both analyzers allows for focusing 
on the precursor and fragment ions over longer times and increases the 
sensitivity. Typically, MRM is used for detection of analytes with known 
fragmentation properties in complex samples.   
 
 
Figure 14: Multiple scan modes routinely used in tandem mass spectrometry (MS/MS) [56]. 
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2.3.4 Matrix effects 
 
As noted earlier in 2.3.1, a drawback of ESI-MS is the occurrence of matrix effects. 
Matrix effects were originally discussed by Kerbale and Tang, who showed that the 
response of organic bases decreased when increasing the concentrations of other 
organic bases [41].  
Matrix effects are the alteration of ionization efficiency by the co-eluting compounds 
and can lead to a significant increase or decrease in the response of an analyte in a 
matrix sample compared to the same concentration in a neat sample [57,58]. 
The mechanism by which matrix effects occur is still unclear, but is thought to be as a 
result of competition between the interfering matrix components and the analyte 
during the ionization process for access to the droplet surface and subsequent 
emission into the gas phase.  
Generally, matrix effects vary from sample to sample and from analyte to analyte [58-
64]. They also depend on the sample preparation procedure, the mobile phase, the 
chromatographic separation and the ionization mode [65]. These compounds are 
known to cause matrix effects: anticoagulants, dosing vehicles, salts, fatty acids, 
triglycerides, phospholipids and constituents of sampling material (e.g. polymers) [66-
69]. 
It must be kept in mind that the enhancement in the response of the analyte may 
sometimes come from some other compound with the same m/z of both the parent 
and the product ions [70]. This kind of increase in signal intensity differs from the 
ionization enhancement by matrix effects.  
Matrix effects can cause significant errors in the sensitivity, accuracy and precision of 
an analytical procedure [71]. Thus, according to the FDA guidelines [72,73], the 
evaluation of matrix effects is required as part of a quantitative method development.  
 
Although how to evaluate and eliminate the presence of matrix effects is not stated in 
the guidelines, there are two most commonly used methods to study matrix effects.  
A) Post extraction supplementation technique 
The post extraction supplementation technique has been developed by Matuszewski 
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et al. for quantitative measurement of matrix effects [60].  A spiked neat sample is 
analyzed with LC-ESI-MS/MS and gives the MS response of the peak area          
Aneat sample. A spiked matrix sample at the same concentration gives the MS response 
of peak area Amatrix sample. The matrix effect can be calculated with the formula 
according to Niessen et al. and Taylor [57,58]: 
                   (Equation 1) 
A value of 0 indicates no matrix effects, a negative value indicates ion-suppression 
and a positive value indicates ion-enhancement due to coeluting sample compounds.  
In addition, matrix effects can be calculated as a relative difference of slops of two 
calibration curves constructed from the spiked neat sample and the spiked matrix 
sample at the corresponding concentrations [74]. In this application, the intercepts of 
both calibration curves should be negligible. This indicates that the matrix effects are 
independent of the concentration of the analyte.  
B) Post-column infusion 
A spiked neat solution is constantly infused into the LC eluent via a T-union inserted 
between the LC column and the MS detector.  The MS response of this solution is 
monitored while injecting a blank matrix sample for SPE-LC-MS/MS analysis. The 
constant MS response (baseline) of the spiked neat solution varies if compounds 
elute from the LC column which suppress or enhance the ionization process [75]. 
 
The matrix effects can be decreased by injecting less sample or a diluted sample. 
However, this is accompanied with less detection sensitivity [76]. Another measure to 
reduce matrix effects is to minimize the number of coeluting compounds. This can be 
accomplished by more effective extraction/clean-up techniques (e.g. SPE extraction) 
or improving chromatographic resolution of the analyte peak from the peaks of 
interfering matrix compounds [77-84].  
The matrix effects can only rarely be fully eliminated during method development. 
Thus, the matrix effects are practically unavoidable in ESI-MS and need to be 
compensated for to improve the quality of the analytical results. The use of an 
Internal Standard (IS) is recommended, as the extraction- and ionization efficiency 
are expected to be identical with regard to the analyte and the IS [52,85].  
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The IS method is based on a comparison of the intensity of the signal corresponding 
to the analyte with one of the IS. This comparison allows the elimination of various 
error sources. As the analyte and the IS undergo the same losses in the extraction 
steps and the same errors in the ionization step, their ratio remains unchanged [52]. 
It is recommended to add the IS as early as possible in the analysis procedure. This 
allows the IS to be treated exactly the same as the analyte and leads to the 
maximum precision of the analysis method.  
The physical and chemical properties of the IS should be as close as possible to 
those of the analyte [52,86]. There are three categories of IS: structural analogues 
labeled with stable isotopes, structural homologues and compounds from the same 
chemical family. In this work, two different Internal Standards are used for the 
quantitation of Cyclosporine A: the isotope labeled deuterated Cyclosporine A (D12-
Cyclosporine A) and the structural homologue Cyclosporine D.  
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2.4 Target analytes: Immunosuppressants 
 
Immunosuppressants are powerful drugs that affect the immune system. They are 
used to prevent the body from organ rejection in post-transplantation patients and 
slow down the immune response in autoimmune disease therapy [87].  
Immunosuppressants can be classified based on their primary sites of action. The 
most commonly used immunosuppressants include cyclosporine, tacrolimus, 
sirolimus, everolimus, glucocorticoids, azathiopurine and mycophenolate mofetil 
[88,89].  
Due to the availability of appropriate immunosuppressive regimens, the outcome of 
post-transplatation patient care has been significantly improved over the last decades 
[89].  
However, all of these immunosuppressants have variable pharmacokinetic profiles, 
relative narrow therapeutic ranges, and show toxic side effects [90-94]. The required 
dosage of immunosuppressants also varies in different individuals and ethnicities. In 
transplant recipients, both supratherapeutic and subtherapeutic drug concentration 
can have devastating effects. Thus, individualizing the drug therapy of patient is 
recommended to obtain the optimum balance between the therapeutic efficiency and 
the risk of experiencing toxic side-effects. This has been achieved by therapeutic 
drug monitoring (TDM) during drug treatment [95]. 
Therapeutic drug monitoring (TDM) is the measurement of drug levels in the blood at 
timed intervals in order to maintain a blood level within the narrow therapeutic range 
by adjusting the individual dosage. Immunosuppressants are mainly bound to 
erythrocytes [96-103]. 58% of Cyclosporine A, for example, is present in erythrocytes 
at a concentration of 500 µg/L at 20 °C [104]. Thus  TDM of immunosuppressants has 
to be performed in whole blood. There are two categories of available analytical 
techniques for TDM of immunosuppressants: immunoassay and LC based methods 
[89]. During last 10-15 years, LC-MS/MS has gained increasing popularity in clinical 
laboratories due to its high selectivity and sensitivity, as mentioned previously in 2.3. 
At present, the most common method for pretreatment of whole blood samples prior 
to SPE-LC-MS/MS analysis of immunosuppressants is protein precipitation 
[105,106]. However, by applying the analysis platform described in this work, the 
24 
 
blood level of immunosuppressants can be directly determined from whole blood 
without any manual pretreatment.  
In this work, the immunosuppressant Cyclosporine A is used as the model analyte. 
For determination of the blood level of Cyclosporine A, two different Internal 
Standards are used: D12-Cyclosporine A and Cyclosporine D. Figure 15 shows the 
structural form of Cyclosporine A and its Internal Standards.  
 
 
Figure 15: Structural formula of Cyclosporine A, Cyclosporine D and D12-Cyclosporine A. 
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3 Experimental Part 
 
3.1 Set-up of a fully automated analysis platform  
  
Towards a total automation of LC-MS/MS analysis of whole blood samples a 
dedicated instrumental platform has been developed and is described in the 
following. This platform enables direct injection, in-line processing and on-line SPE-
LC-MS/MS analysis of drugs and endogenous, low-molecular weight compounds 
present in whole blood samples. 
The fully automated analysis platform consists of an autosampler, an on-line SPE 
unit, several HPLC pumps, a UV-VIS detector and a tandem mass spectrometer 
(Figure 16). 
 
 
Figure 16: Instrumental set-up of the fully automated analysis platform. 
 
This platform represents a total analysis system (TAS). As shown in Figure 17, it 
consists of the following units: sample handling/injection unit, processing unit, clean-
up unit, separation unit, detection unit and data managing unit.   
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Figure 17: Total analysis system for direct and automated determination of drugs in whole 
blood. 
 
The sample handling/injection unit is a XYZ - autosampler, which has been 
configured in cooperation with LEAP Technologies (Carrboro, NC, USA). The 
software Chronos was modified and adjusted for controlling and timing of this 
dedicated autosampler in cooperation with Axel Semrau (Sprockhövel, Germany).   
 
 
Figure 18: Modules of XYZ – Autosampler. 
 
As shown in Figure 18 the autosampler is composed of a bar code reader, a heatable 
vortexer, two liquid handling units and two processing units, which independently 
convert anticoagulated whole blood into the novel blood matrix, i.e. cell-disintegrated 
blood (CDB). 
27 
 
3.1.1 Liquid Handling/Injection Unit: C-1 module 
 
This unit is composed of a barcode reader for automatic identification of samples, a 
vortexer for sample mixing, and a DLW liquid handling unit for sampling and injection. 
The DLW liquid handling unit consists of a DLW injection adapter (Figure 19) with 
syringe (100 µL), a solenoid/actuator valve, two inlets for DLW active micro pumps, a 
sample holding loop (100 µL), a spring loaded needle guide and replaceable injection 
needle, a DLW wash station, a wash solvent pump station with two active micro 
pumps for DLW wash step and a self-priming PTFE micro pump for external active 
wash of the injection needle. 
 
 
Figure 19: Components of DLW injection module. 
 
For operation of the C-1 module the Chronos software was programmed accordingly.  
A sedimented sample of anticoagulated blood stored in the sample hotel at 4 °C, is 
transferred to the vortexer for mixing. The homogenized whole blood sample is 
identified by a barcode reader (if required) and placed back into the sample hotel. A 
defined amount of an air segmented blood sample is aspirated by the syringe needle 
and stored into the holding loop. After sampling, the injection needle is washed from 
outside using the active wash option. This is followed by aspiration of a defined 
volume of IS stored in the sample hotel, in case an in-line addition of IS is required. 
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Finally, all segmented fluids present in the injection needle and holding loop, 
respectively, are injected into the sample loop (100 µL) via the injection valve. By this 
the in-line processing and on-line SPE step are initiated. Simultaneously, the liquid 
handling unit is moved to the DLW wash station and the whole sample path is 
washed from the rear with up to two solvents.  
 
 
Figure 20: DLW wash / injection module and principle. 
 
The principle of the DLW wash module is displayed in Figure 20. The two active 
micro pumps at the wash solvent pump station deliver a defined amount of wash 
solvent to the injection adapter. The solenoid/actuator valve functions in a precise 
manner, in starting/stopping the solvent delivery system and solvent switching. As a 
consequence all parts which have been in contact with the sample, i.e. the highly 
viscous blood samples, are completely washed from both inside and outside.        
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As mentioned before, the injection needle has to be washed externally after 
sampling, in order to get rid of contamination of residual sample components. 
However this wash step cannot be implemented into the DLW wash module.  
Therefore, a special active wash module (Figure 21) has been developed by 
combining a self-priming PTFE micro pump with the DLW wash station (C-2). The IN 
port of the micro pump was connected to the wash solvent bottle, and the OUT port 
was connected to the wash 1 station (Figure 21) of the DLW wash module (C-2). 
After sampling the injection needle is inserted to wash 1 station, and the micro pump 
is activated. The wash solvents flow from the bottom of wash 1 station and clean the 
injection needle externally in backflush direction.  
 
 
Figure 21: Active wash module. 
 
 
3.1.2 Liquid Handling / Injection Unit: C-2 Module 
 
The operation of the C-2 module was programmed with the Chronos software.  A 
sedimented sample of anticoagulated blood stored in the sample hotel at 4 °C, is 
transferred to the vortexer for mixing. The homogenized whole blood sample is 
identified by the barcode reader (if required) and placed back into the sample hotel. A 
defined volume (e.g. 40 µL) of an air segmented blood sample is aspirated into the 
special stainless steel processing needle. This needle has an inner diameter of 1.6 
mm and a volume of 116 µL. After sampling, the processing needle is washed 
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externally using the active wash option. Then the processing needle is inserted into 
the standpipe for snap-freezing, as described in 3.1.3. After removal of the 
processing needle from the standpipe, the snap-frozen sample is allowed to melt at 
room temperature. Then the processed blood sample (cryo CDB) is deposited into a 
second vial placed in the sample hotel.  The processing needle is moved to the DLW 
wash station, and the whole sample path is washed with water and organic solvent. 
Finally, the inner lumen of the processing needle is dried with nitrogen.  
 
 
3.1.3 Processing Units 
There are two embedded processing units in this platform for the two independent 
procedures to convert anticoagulated whole blood into CDB.  
One of the processing units is for heat-shock treatment of anticoagulated whole 
blood. As shown in Figure 22 A, a heated stainless-steel HPLC capillary (300 x 0.5 
mm ID) is placed in a column oven and used as processing device. The whole blood 
sample is injected into and pumped through this heated capillary under defined 
conditions.  
 
                 A.             B.  
Figure 22: A. Device for heat-shock treatment; B. Device for cryogenic treatment. 
 
The other processing unit is for cryogenic treatment of anticoagulated whole blood. 
As shown in Figure 22 B, a stainless-steel syringe-needle is used as processing 
device. The blood sample is aspirated and snap-frozen by contacting the syringe 
needle with liquid nitrogen followed by slow thawing. Liquid nitrogen is contained in a 
stainless-steel thermo-flask (Thermolyne® Brand Thermo-Flask®), which is sealed 
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with a special cover board.  
In the center of the cover board a standpipe is located, which serves as a sleeve for 
the processing needle. The sleeve can be filled with liquid nitrogen through a Teflon 
tube, one end of which is located at the bottom of the thermo-flask. At the moment 
the autosampler places the processing needle into the standpipe, a valve closes the 
overpressure line. By this liquid nitrogen is forced through the Teflon tube into the 
standpipe and snap-freezes the blood sample contained in the processing needle. 
This valve-triggered freezing process was established together with LEAP 
Technologies (Carrboro, NC, USA). For more technical information see S. Dai patent 
application (WO 2010/065145A1).  
 
 
3.1.4 Clean-up unit  
 
After conversion of whole blood into CDB this fluid contains all matrix components of 
whole blood. Thus CDB has to be pretreated by solid phase extraction (SPE) prior to 
LC-separation.  
For the clean-up of CDB a SPE column coupled with an in-line filter was installed. 
Different SPE columns and filters were tested during method development. 
The SPE column and the filter were connected to different 6-port switching valves of 
the on-line SPE unit. Thus, the SPE column and the filter were separately washed 
and reconditioned after every sample. In this way, the lifetime of both SPE column 
and filter was extended effectively. This not only reduces costs, but also improves 
robustness of the overall analysis procedure.  
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3.1.5 Separation unit 
 
After fractionation of CDB the extracted analytes were transferred on-line from the 
SPE column to an analytical column and separated there. The preferred analytical 
column for the separation of the model compounds immunosuppressants was a 
pentafluorophenyl (PFP) column (50 x 2.1 mm ID, dp 5 µm). The model analyte 
Cyclosporine A is very strongly bound to the SPE material investigated. Thus only an 
eluent with a high amount of organic solution can desorb the target analyte from the 
SPE column. However, under this condition no retention and thus no separation of 
the analyte(s) on the analytical column can be achieved. This problem was solved by 
a so-called in-line dilution step.  
For that purpose a T union was placed in front of the analytical column (Figure 35). 
This configuration allows the addition of an aqueous mobile phase via the T union to 
the mobile phase eluting from the SPE-column. By adjusting appropriate flow-rates 
any composition of the mobile phase being optimal for the retention/separation of the 
target analyte(s) can be achieved.  
 
 
3.1.6 Detection unit 
 
For the detection of drugs and endogenous, low-molecular weight compounds two 
detectors were integrated in the platform.  
First, a UV-VIS detector was used for on-line monitoring the elution profiles of matrix 
components. In SPE-based sample clean-up, the UV-VIS detector was used to 
monitor the protein matrix at 280 nm and the hemoglobin fraction at 428 nm.  
Second, a tandem mass spectrometer was used for selective and sensitive detection 
of the low-molecular weight model compound, i.e. the immunosuppressant 
Cyclosporine A. 
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3.2 Development of a SPE-LC-MS/MS method for direct 
analysis of Cyclosporine A in whole blood via heat-
shock treatment 
 
The development of an on-line SPE-LC-MS/MS method for direct analysis of drugs 
and endogenous, low-molecular weight compounds in blood samples includes 
implementation and optimization of the SPE based sample clean-up step, the LC 
based separation step and the MS/MS detection. In addition, the operational 
parameters for the sample handling/injection unit and as well as the processing unit 
(heat-shock treatment) of whole blood had to be adopted and optimized, respectively.  
 
 
3.2.1 Optimization and standardization of sample handling/injection 
 
The standardization of handling/injection of whole blood samples involved the 
following operational steps: 
1) Mixing of sedimented blood sample  
2) Addition of Internal Standard (IS) if required 
3) Optimization of sample segmentation by air and liquids 
4) Optimization of syringe speed for aspiration and dispensing  
5) Optimization of both in-between and after injection wash of injection needle 
 
 
3.2.1.1 Sample mixing 
 
Whole blood represents a heterogeneous, i.e. a two-phase system composed of 
blood plasma and blood cells. Thus, blood cells sediment on standing.  
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A sedimented whole blood sample present in a HPLC vial and located in the sample 
hotel is placed into the vortex as shown in Figure 23 A, and shaken (Figure 23 B) to 
yield a homogenized sample ready for injection as shown in Figure 23 C.  
 
A.    B.    C.    
Figure 23: Sequence of mixing a sedimented sample of whole blood 
 
 
3.2.1.2 Addition of Internal Standard (IS) 
 
The Internal Standard (IS) for the analysis of the model analyte Cyclosporine A is 
Cyclosporine D or D12-Cyclosporine A. These compounds are very hydrophobic and 
thus only soluble in organic solvents. In this work, dimethyl sulfoxide (DMSO) is used 
for preparation of the Internal Standard. The addition of DMSO to a sample of whole 
blood even improves the conversion of whole blood sample into CDB [16]. As DMSO 
becomes solid when stored in the sample hotel at 4 °C, mixtures of DMSO and 
sodium chloride solution were investigated.  
It turned out, that a mixture of DMSO/NaCl (80/20 v/v) provided the best result with 
regard to solubility at 4 °C.  
 
 
3.2.1.3. Sample Segmentation 
 
So far, a whole blood sample has been air segmented before injection, in order to 
avoid the lysis of the blood cells when in contact with mobile phase [15]. Yet, during 
in-line heat-shock treatment, an additional temperature dependent convection of the 
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blood sample within the heated capillary caused a mixing of blood cells with the 
mobile phase. This dilution leads to a modified hematocrit. Thus, the heating time 
which is dependent on hematocrit, cannot be adjusted properly in order to 
disintegrate the blood cells in a highly efficient and reproducible way. In addition, the 
dilution with the mobile phase causes unwanted hemolysis.  
Thus, much more efficient sample segmentation has been developed by adding 
additional plugs of sodium chloride solution. In addition, volume and position of those 
plugs were optimized.  
 
 
Figure 24: Instrumental set-up for optimization of sample segmentation 
 
The system configuration for optimization of the sample segmentation is shown in 
Figure 24. The dilution of the processed blood sample, i.e. CDB was directly 
monitored with a UV-VIS detector. The wavelength was set to 600 nm, the absorption 
minimum of hemoglobin, because the detection of hemoglobin in CDB samples at 
428 nm (maximum absorption of hemoglobin) exceeded the linear measuring range. 
As shown in Figure 25, addition of a post-sample sodium chloride solution plug 
considerably reduced the dilution of the blood sample, and thus its elution time. This 
is reflected in a sharper dispersion profile, i.e. peak compression of the hemoglobin 
fraction (Figure 25: compare the red and green chromatograms to the pink one).  
The sample segmentation was further optimized by introducing a pre-sample sodium 
chloride solution plug (the blue chromatogram in Figure 25). By this measure the 
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peak maximum shifted forwards and the overall elution time of the CDB matrix was 
further reduced from 3 minutes to 2 minutes in total.  
It is clear, pre- and post-sample sodium chloride solution plug coupled to air segment 
efficiently protected whole blood sample from dilution by aqueous mobile phase and 
lysing of blood cells before in-line processing.  
 
 
Figure 25: Optimization of sample segmentation: Elution profiles of a differently segmented 
blood sample. 
 
 
3.2.1.4 Optimization of syringe speed for aspiration and dispensing 
 
A major problem to be solved during the development of the described instrumental 
platform was the dosing and injection of a sample of whole blood.  
For conventional applications (i.e. diluted and/or precleaned samples), the speed of 
the injection syringe is set to 100 µL/s. However, a sample of whole blood is very 
viscous and thus contaminates the injection line very easily. This leads to significant 
carry over effects. In this work it was found that sampling of whole blood at a syringe 
speed of 2 µL/s in combination with the optimized aspiration and segmentation 
sequence completely reduced carry over effects.  
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3.2.1.5 Optimization of in-between and after injection wash of injection needle 
 
As mentioned above (3.1.1), the injection needle should be washed from outside by 
active wash after sampling of blood. In this step, the needle penetration at wash 1 
station for active wash was optimized. It should be deep enough, so that the outer 
surface of the needle, which has been in contact with blood, can be completely 
cleaned by wash solvent. On the other hand, there should be some space between 
the bottom of wash 1 station and the tip of the injection needle. This prevents that the 
wash solvent is pumped into the lumen of the needle.  
For wash of the whole sample path using DLW wash function (3.1.1), the 
components of the wash solvents had to be optimized. Residual blood is removed by 
rinsing with an aqueous solvent. Remaining analyte(s) on the surface of the injection 
path is washed away with an organic solvent. It turned out, that the optimal 
combination for the DLW wash is: H2O/ACN (95/5, v/v, wash 1) for the aqueous 
needle rinse and a mixture of organic solvents (wash 2) for the organic needle rinse. 
The ACN is present in wash 1 to prevent microbial growth in the reservoir.  
It is known that adding an organic solvent to a biological sample causes protein 
precipitation. Therefore the organic solvent should never come in contact with the 
blood sample. Otherwise the injection line would get clogged. So after the sample 
injection, the syringe and injector was washed first with wash 1, then with wash 2, 
and again with wash 1 to remove organic solvent.  
 
 
3.2.2 In-line processing of blood samples by heat-shock treatment 
 
The in-line processing of anticoagulated whole blood by heat-shock treatment and 
the corresponding processing parameters (tmin, tmax, theat) were described by 
Milojković [16]. The same processing parameters determined by Milojković were 
used here. For a mixture of whole blood and IS in 2.5 vol% DMSO, the optimal 
heating time is 13 seconds at 75 °C. The timing of the sample and mobile phase, 
respectively, can be achieved by adjusting the flow rate. The flow rate is calculated 
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by dividing the volume (59 µL) of the heated capillary (300 x 0.5 mm ID) by the 
heating time (13 seconds), yielding 270 µL/min. 
Besides temperature and heating time, the processing procedure is predominantly 
affected by dilution of blood sample and lysis of blood cells by the aqueous mobile 
phase (see also 3.2.1.3). In order to minimize these effects, the blood sample has to 
be segmented accordingly (see 3.2.1.3). In addition, the dead volume between the 
injection port and the heated capillary has to be as small as possible. This could be 
achieved by connecting the heated capillary directly to the injection valve, as shown 
in Figure 26. Instead of placing the heated capillary in a column oven (Figure 22 A, 
Figure 24), a heated sleeve (250 x 1.587 mm ID, AgileSLEEVE Plus Capillary 
Heater) was used to heat the stainless-steel HPLC capillary. 
 
 
Figure 26: Instrumental set-up for monitoring the heat-shock treatment process of whole blood. 
 
The duration of the total blood-processing procedure was monitored by connecting 
the outlet of the heated capillary to a UV-VIS detector. 20 µL of whole blood were 
injected into the sample loop and pumped through the heated capillary to the UV-VIS 
detector with a flow rate of 270 µL/min and a mobile phase composed of H2O/ACN 
(95/5, v/v).  
As shown in Figure 27, the overall duration for in-line processing of 20 µL whole 
blood was 45 seconds.  
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Figure 27: Monitoring of the overall heat-shock treatment process of whole blood via a UV-VIS 
detector: Elution profile of a segmented and processed blood sample. 
 
Comparison of Figure 27 and Figure 25 shows, that reduction of the dead volume 
between the injection port and the heated capillary shifted the peak maximum 
forwards. In addition, the peak-dispersion was significantly diminished, as seen in the 
reduction of the half-peak-width from 10 seconds to 7 seconds.  
 
 
3.2.3 Development of an on-line SPE method for clean-up of a cell-
disintegrated blood (CDB) sample 
 
For on-line solid phase extraction of processed whole blood (i.e. CDB), attentions 
should be taken in order to prevent clogging of capillaries and column sieves by 
particles / precipitate. First, the inner diameter of capillaries between sample inlet and 
SPE-column as well as between SPE-column and valve-port “waste” should be 0.5 or 
0.8 mm. Furthermore, a replaceable in-line filter should be inserted between sample 
inlet and SPE column.  
The most essential part of the in-line filter is a special three-layered stainless steel 
sieve, the smallest pore diameter of which is 1µm. This sieve is positioned in the 
housing, which is free of dead volume, and sealed by a Teflon seal together with a 
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conical pressure screw (Figure 28). As only one sieve is used in this in-line filter, it is 
also called (in-line) single sieve filter. Because of the small pore diameter of the 
sieve, all the components and agglomerates formed during the in-line heat-shock 
treatment of blood samples and being larger than 1 µm are withheld by the in-line 
filter. This prevents the clogging of the SPE column and even the analytical column. 
 
  
Figure 28: Parts of single sieve filter. 
 
Clean-up of the processed blood sample, i.e. cell-disintegrated blood (CDB) was 
performed on-line using a TurboFlow SPE column (Cyclone-P, 50 x 0.5 mm ID) 
coupled to an in-line single sieve filter. The first step to set-up an on-line SPE system 
was to determine the valve switching times (3.2.3.1). After that, the wash process for 
the single sieve filter and the SPE column was optimized separately (3.2.3.2).  
 
 
3.2.3.1 On-line SPE: Determination of valve switching times 
 
The operational procedure and steps to determine valve switching times are 
described in the next paragraphs.  
 
Step 1: Determine time for complete depletion of sample matrix = tM  
After in-line processing of whole blood, the cell-disintegrated blood matrix is 
fractionated into analyte and sample matrix. The target analyte is retained on the 
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stationary phase of the SPE column, and the residual sample matrix is flushed to 
waste. 
When depleting a protein matrix, care should be taken to ensure that the loading 
mobile phase does not possess denaturing properties. With regard to the amount of 
organic modifier, it is recommended to use less than 15 vol% methanol, or less than 
10 vol% acetonitrile or less than 5 vol% isopropanol. For displacement of protein 
bound analytes, such as immunosuppressant, the addition of 2 to 5 vol% of ACN and 
2 to 10 vol% of MeOH is recommended. In this work, a mixture of 95/5 H2O/ACN has 
been used as mobile phase for fractionation.  
In order to determine the parameter tM, the TurboFlow SPE column (Cyclone-P, 50 x 
0.5 mm ID) was directly coupled to UV-VIS detector (Figure 29). Then the elution 
profile of the CDB matrix was monitored at 428 nm, the absorption maximum of 
hemoglobin.   
 
 
Figure 29: On-line SPE: Instrumental set-up for the determination of the SPE-parameters tM 
and tA. 
 
The TurboFlow SPE column (50 x 0.5 mm ID) requires a high flow rate for sample 
fractionation. Such a high flow rate (2 mL/min) and linear flow velocity (10.2 m/min), 
respectively, is not compatible with the ones (270 µL/min, linear velocity: 1.38 m/min) 
applied for the heat-shock treatment. The solution was, to store the processed 
sample, i.e. CDB in a holding loop (254 x 1.0 mm ID, 200 µL holding volume). This 
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technical “trick” allows pumping the CDB sample through the TurboFLow SPE 
column at the required flow rate of 2 mL/min. The elution profile of the CDB matrix 
was monitored at 428 nm, i.e. the absorption maximum of hemoglobin. A 
representative elution profile of a CDB matrix is shown in Figure 30. The matrix 
elution time tM for 20 µL of processed whole blood (CDB) on the TurboFlow SPE 
column (Cyclone-P, 50 x 0.5 mm ID) amounts to 55 seconds at a flow rate of 2 
mL/min.   
 
 
Figure 30: On-line SPE: Monitoring of elution profile of CDB matrix and determination of SPE-
parameter tM. 
 
Step 2: Determine breakthrough time (tA) of analyte 
For the determination of the parameter value tA the same instrumental set-up as for 
tM (Figure 29) is used. Instead of a UV-VIS detector, the tandem mass spectrometer 
is used to monitor the breakthrough profile of the analyte Cyclosporine A on the 
TurboFlow SPE column. 
A standard solution of the analyte is injected onto the SPE column. The SPE column 
is operated at a high flow rate of 2 mL/min. After fractionation for 12 minutes with 
H2O/ACN (95/5, v/v) at 2 mL/min, the extracted analyte is desorbed with 100 % 
MeOH (see also step 4) at the same flow rate for 4 minutes. The resulting elution 
profile of the analyte is shown in Figure 31. No signal is detected for the first 12 
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minutes (no breakthrough). After switching to 100 % MeOH, the analyte is 
immediately desorbed. Thus, the breakthrough time of analyte tA exceeds 12 minutes 
at a flow rate of 2 mL/min.   
 
 
Figure 31: On-line SPE: Monitoring of breakthrough of model analyte CyA and determination of 
SPE-parameter tA. 
 
Step 3: Calculate the first switching time for both switching-valves 
The first switching time (tV1) for both switching-valves terminates the fractionation 
step. Simultaneously, the SPE-column is coupled with the analytical column. The 
parameter tv1 is calculated as follows:  
tv1 = tprocessing step + tM + x   (Equation 2) 
     = 45 s + 55 s + 10s = 110 s 
x (= 10 s) is the add-on time for security / robustness reasons.  
 
Step 4: Determine desorption / transfer time (tT) of analyte(s) from SPE column  
The instrumental set-up for the determination of tT is displayed in Figure 32. 
First, a standard solution of the analyte is injected, and pumped at a flow rate of 270 
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µL/min through the heated capillary (75 °C) with th e mobile phase used for the 
fractionation step H2O/ACN (95/5, v/v) and “parked” in the holding loop (see Figure 
32 A). After 45 seconds, the flow rate is enhanced to 2 mL/min for 65 seconds in 
order to operate the TurboFlow SPE column under optimal conditions for extraction 
of the target analyte.  
Switching the valve after 110 seconds couples the SPE column with the mass 
spectrometer. The analyte is back-flushed and transferred from the SPE column to 
the MS detector. The transfer time is defined as complete elution of the analyte from 
the SPE column.  
 
A.  
B.  
Figure 32: Instrumental set-up for the determination of the SPE-parameter tT. 
A) Extraction of target analyte on TurboFlow SPE column; B) Desorption of target 
analyte from TurboFlow SPE column and transfer to analytical column  
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To determine the optimal amount of organic modifier for the elution step, a series of 
isocratic elutions with varying organic concentrations is run. A standard solution of 
Cyclosporine A is directly injected onto the TurboFlow SPE column (Cyclone-P, 50 x 
0.5 mm ID) and then eluted by a mobile phase containing different amounts of 
Methanol. In order to assure quantitative elution, i.e. transfer to a series-connected 
analytical column, an additional desorption step with 100% MeOH is applied. The 
resulting elution profiles are shown in Figure 33. As demonstrated in chromatograms 
C and D, memory effects occur when eluting the target analyte with less than 80% of 
MeOH. 
 
 
Figure 33: On-line SPE: Elution profiles of Cyclosporine A from the SPE column under varying 
isocratic conditions. 
A) MeOH/H2O, 100/0, v/v; B) MeOH/H2O, 90/10, v/v; C) MeOH/H2O, 80/20, v/v;  
D) MeOH/H2O, 70/30, v/v; E) MeOH/H2O, 60/40, v/v 
 
As a result, a mobile phase composed of 100 % MeOH was chosen for the elution 
and transfer step, respectively. 
46 
 
As shown in Figure 34, the total elution/transfer time of analyte CyA from the 
TurboFlow SPE column to the analytical column was 45 seconds at 200 µL/min (see 
3.2.4).  
 
 
Figure 34: On-line SPE: Monitoring of desorption and transfer of model analyte CyA from the 
SPE column and determination of SPE-parameter tT. 
 
Step 5: Calculate the second switching time for both switching-valves 
The second switching time (tV2) for both switching-valves terminates the transfer step. 
Simultaneously, the analytical column is decoupled with the SPE-column. The 
parameter tv2 is calculated as follows:  
tv2 = tv1 + tT + y     (Equation 3) 
     = 110 s + 45 s + 15s = 170 s 
y (= 15 s) is the add-on time for security / robustness reasons.  
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3.2.3.2 Optimization of washing step for in-line filter and SPE column  
 
As mentioned above, the smallest pore diameter of the three-layered stainless steel 
sieve in the in-line filter is 1µm. Thus, all components and agglomerates formed 
during the in-line heat-shock treatment of blood samples and being larger than 1 µm, 
are withheld by the in-line single sieve filter. This prevents the clogging of the SPE 
column and even the analytical column. However, these residues can cause 
significant carry over effects. This problem is solved by back-flushing the in-line 
single sieve filter during the transfer step. First, an aqueous mobile phase (H2O/ACN, 
95/5, v/v) is used to remove the residues from the filter at a flow rate of 2 mL/min for 
30 seconds. Secondly, any remaining analyte(s) on the surface of the filter is washed 
away using a mixture of Acetonitrile /Isopropanol/Acetone (45/45/10, v/v/v) at a flow 
rate of 2 mL/min for 30 seconds.  
After transfer of analyte from the TurboFlow SPE column (Cyclone-P, 50 x 0.5 mm 
ID) to the analytical column, the SPE column is disconnected from the analytical 
column and series-connected with the in-line single sieve filter (see Figure 41). A 
mixture of organic solvent is used to clean the in-line single sieve filter and 
TurboFlow SPE column (Cyclone-P, 50 x 0.5 mm ID) at a flow rate of 2 mL/min for 
185 seconds (see 3.2.6).  
 
3.2.4 Optimization of the analytical separation of the model 
analyte(s) 
 
In this work, a pentafluorophenyl (PFP) analytical HPLC column (Hypersil GOLD 
PFP, 50 x 2.1 mm ID, dp 5 µm) with a guard column (Hypersil GOLD PFP, 10 x 2.1 
mm ID, dp 5µm) both operated at 70°C in a column ov en was used for the separation 
of the model analyte(s). The separation of the analyte(s) is influenced by the mobile 
phase used for the transfer step of the analyte(s) from the SPE column to the 
analytical column. Therefore optimal transfer and separation conditions for the model 
analyte(s) had to be investigated.  Finally, the wash process for the analytical column 
was optimized. 
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3.2.4.1 Optimization of transfer conditions  
 
This goal was achieved by a so-called in-line dilution step. As shown in Figure 35 a 
mixing T union was installed in front of the analytical column and was connected to 
pump 2 and the TurboFlow SPE column via switching valve 2 (SV 2). This 
instrumental set-up allows the addition of an aqueous mobile phase by pump 2 to the 
eluate of the SPE column before it reaches the top of the analytical column. In this 
way the amount of organic modifier can be decreased to such an extent that the 
analyte(s) are enriched at the top of the analytical column (peak compression or 
focusing) prior to their separation. 
 
 
Figure 35: Instumental set-up for in-line dilution of the eluate from the SPE column. 
 
In order to find out the optimal composition, i.e. the amount of organic modifier of the 
mobile phase for the separation of the model analyte(s), a series of experiments were 
carried out (Figure 36). 
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Figure 36: Separation profiles of Cyclosporine A from the analytical column using decreasing 
amounts of organic modifier. 
A) MeOH/H2O, 90/10, v/v; B) MeOH/H2O, 80/20, v/v; C) MeOH/H2O,70/30, v/v;    
D) MeOH/H2O, 60/40, v/v; E) MeOH/H2O, 50/50, v/v; F) MeOH/H2O, 40/60, v/v;                
G) MeOH/H2O, 30/70, v/v; H) MeOH/H2O, 20/80, v/v 
 
For this purpose, a standard solution of Cyclosporine A was directly injected onto the 
analytical column (Hypersil GOLD PFP, 50 x 2.1 mm ID, dp 5 µm) and eluted by a 
mobile phase containing different amounts of MeOH. In order to assure quantitative 
elution of the analyte(s) from the analytical column, an additional desorption step with 
100% MeOH has been applied. The resulting chromatograms are shown in Figure 
36. No retention of the model analyte Cyclosporine A on the analytical column is 
achieved when eluting with more than 80% of MeOH, as demonstrated in 
chromatogram A and B.  
As a result, a mobile phase composed of MeOH/H2O (30/70, v/v) was chosen as the 
optimal mobile phase. This decision was made with regard to other 
immunosuppressants, which are less hydrophobic than Cyclosporine A and thus can 
be eluted from the analytical even with less than 80% MeOH. 
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The in-line dilution needed for the transfer step can be calculated using equation 4. 
Pump 3 is the eluting pump used for the transfer step and pump 2 is the diluting 
pump: 
 (Equation 4) 
 
The total flow rate entering the analytical column (Hypersil GOLD PFP, 50 x 2.1 mm 
ID, dp 5 µm) after the mixing T union was set to 0.7 mL/min. In order to ensure an 
optimal timing for the transfer step, the flow rate of pump 3 should be as high as 
possible. This was achieved by setting the mobile phase of pump 2 during the 
transfer step to 100% water. As the “%MeOH of pump 2” is 0% and “%MeOH of 
pump 3” is 100%, the flow rate of pump 3 during the transfer step is calculated 
according to equation 3, and amounts to 0.2 mL/min.  
 
 
3.2.4.2 Optimization of the separation step on the analytical column 
 
In order to achieve an optimal separation and timing, a gradient elution was applied. 
It turned out, that the optimal conditions for the starting mobile phase is MeOH/H2O 
(70/30, v/v). This is followed by a linear gradient of MeOH from 70% to 95% within 60 
seconds. Finally, isocratic conditions for additional 60 seconds completed the 
separation step. 
 
 
3.2.4.3 Optimization of the washing step for the analytical column  
 
After separation of the analyte(s) on the analytical column, the analytical column was 
washed for 120 seconds at a flow rate of 0.7 mL/min to reduce carry over effects. A 
mixture of Acetonitrile/Isopropanol/Acetone (45/45/10, v/v/v) turned out to be the 
most effective solvent. 
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3.2.5 MS/MS detection of the analyte(s) 
 
A home-made flow splitter was used to reduce the flow (0.7 mL/min) of the mobile 
phase eluting from the analytical column to a flow of 0.175 mL/min entering the MS 
ion-source. The splitting of the flow was adjusted to 0.175 mL/min by the length of the 
tubings (0.13 mm ID) fixed to the flow splitter. In this work, the length of the tubing to 
the detector was three times of the one to waste. 
The optimal MS parameters for detection of Cyclosporine A and the Internal 
Standards (IS, Cyclosporine D or D12-Cyclosporine A) were tuned at the reduced 
flow rate of 0.175 mL/min. This was achieved by connecting the solvent flow from the 
syringe pump and the LC pump 2 by a T-union with the ion source. The syringe pump 
infused a standard solution of CyA and IS in EtOH at a flow rate of 25 µL/min. The 
LC pump added a mixture of MeOH/H2O (95/5, v/v) at a flow rate of 150 µL/min.        
In this work, the MS detection was carried out in the ESI+ mode using two different 
mass spectrometers: LTQ VELOS (ThermoFisher Scientific, USA) and Micromass 
Quattro Micro (Waters, USA).  
 
LTQ VELOS Mass Spectrometer: 
After programming the mass spectrometer for ESI mode, the scan parameters were 
set up for a full-scan, single-stage mass analysis. Then the source temperature and 
gas flow were manually adjusted to establish a stable spray of the ESI calibration 
solution infused into the ion-source. The stable spray ensures that the mass analyzer 
is transmitting a sufficient amount of ions to the mass detector. Therefore, the mass 
spectra of the single charged ions in the calibration solution were monitored. Stable 
signals which vary by less than about 15% from scan to scan, indicate that the MS is 
operating properly. The crucial parameters (see below) of the MS were optimized by 
automatic tuning using the ESI calibration solution. It is recommended to calibrate the 
mass spectrometer every one to three months of operation for optimum performance 
over the entire mass range of the detector [107]. 
The most important parameters that affect signal quality in the ESI mode are: 
electrospray voltage, heated capillary temperature (voltage), S-lens RF (radio 
frequency) level, sheath gas flow rate, auxiliary gas flow rate and sweep gas flow 
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rate. The settings for these parameters depend on the solvent flow rate and target 
analyte composition. As the analytical sample was run in high-flow ESI mode using a 
flow rate of 0.175 mL/min in this work, a further tuning with the model analyte(s) in 
the ESI mode is required. The automatic tuning procedure adjusts the voltages 
applied to the ion optics until the ion transmission of the model analyte(s) is 
maximized.  
As a result, the following MS operating parameters were used for detection and 
quantitation of CyA and D12-CyA (Figure 37): 
 
 
Figure 37: MS operating parameters for detection of CyA and D12-CyA using LTQ VELOS in 
ESI+ mode. 
 
Micromass Quattro Micro Mass Spectrometer: 
In order to obtain a high mass accuracy, the MS was tuned and calibrated with 
phosphoric acid in the ESI mode. The tuning parameters in the “ES+Source” and 
“Analyser” menus were adjusted to optimize peak shape and intensity.  
Using a full AutoTune with the model analyte(s) in the ESI mode the voltages applied 
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to the ion optics were further optimized.  
As a result, the following MS operating parameters were used for detection and 
quantitation of CyA and CyD (Figure 38). 
 
 
Figure 38: MS operating parameters for detection of CyA and CyD using Quatro Micro in ESI+ 
mode. 
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3.2.6 Overall analysis cycle 
 
After the optimization and standardization of the sample handling/injection, the in-line 
processing and the detection parameters for on-line SPE-LC-MS/MS analysis of the 
model analyte Cyclosporine A in whole blood, the overall analysis cycle was 
composed. The overall analysis cycle for the direct determination of Cyclosporine A 
in an anticoagulated whole blood sample (20 µL) lasts 11.2 minutes, as shown in the 
representative chromatogram (Figure 39). Individual steps of the overall analysis 
cycle are color coded.  
 
 
Figure 39: Overall analysis cycle for the analysis of Cyclosporine A in a whole blood sample. 
 
The first three steps are related to sample handling and injection (see also 3.2.1) and 
are performed by the autosampler. First, a sedimented whole blood sample is 
remixed by the vortexer. Then the homogenized blood sample is aspirated following 
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the optimized segmentation sequence described in 3.2.1.3. After this step, the 
injection needle is washed externally to remove remaining contaminations. Then the 
segmented blood sample is injected into the sample loop at a speed of 2 µL/min 
(Step 2). After the injection (3.5 min), the injection needle is washed using the DLW 
wash function (Step 3). In parallel, the whole blood sample is processed in-line and 
cleaned up by on-line SPE (Step 4-5). 
For the analysis of Cyclosporine A in whole blood the following filter and columns are 
used: 
Filter: In-line single sieve Filter (free of dead volume, consists of a 
special three-layered stainless steel sieve with the smallest pore 
diameter of 1 µm, a Teflon seal, a housing and a conical 
pressure screw) 
SPE-column: TurboFlow Cyclone-P (50 x 0.5mm ID) 
LC-column:  
 
 
Hypersil Gold PFP guard column + Hypersil Gold PFP column 
(10 x 2.1mm ID+ 50 x 2.1mm ID, dp 5 µm) 
 
Figure 40: System configuration for in-line processing of a whole blood sample and on-line 
SPE-LC-MS/MS analysis of the processed sample (CDB): Analysis cycle steps 4-8. 
 
The system configuration for in-line processing of a whole blood sample followed by 
on-line SPE-LC-MS/MS analysis of the processed sample (CDB) is shown in     
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Figure 40. The detailed instrumental set-up for the analysis steps 4 – 8 is displayed in 
Figure 41.  
The mobile phases used in each steps of the overall analysis cycle are listed in  
Table 1. The software Chronos allows a time optimization of sequential analysis. The 
second analysis starts during the separation step of the analyte(s). Thus the duration 
for the second and following analysis cycle amounts to 7.7 minutes each (Step 4-8), 
instead of 11.2 minutes for the first analysis. 
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Figure 41: System configuration for in-line processing of a whole blood (heat-shock treatment) 
and on-line SPE-LC-MS/MS analysis of the processed sample (CDB): Analysis cycle 
steps 4-7. 
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Table 1: Time table of overall analysis cycle: Flow rates, compositions of mobile phases and 
functions of pump settings. 
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3.3 Evaluation of the total analysis platform (use in-line 
single sieve filter) for quantitation of Cyclosporine A 
after heat-shock treatment of whole blood  
 
The described total analysis platform for the detection and quantitation of 
Cyclosporine A after heat-shock treatment of whole blood has been evaluated with 
respect to the following: 
- Validation parameters 
- Robustness   
 
 
3.3.1 Method validation  
 
The first step to evaluate the described analysis method is to validate it according to 
widely accepted protocols to confirm that the performance of the method meets the 
requirements for the intended application. Reliable analytical results are required to 
comply with international regulations and to ensure patient safety. The U.S.Food and 
Drug Administration (FDA) regulations require the validation of an analytical method 
before and during regular routine use [72]. There are many guidelines for validation 
of analytical assays such as those published by the FDA, the International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceutical for Human Use (ICH), and the Bundesärztekammer…etc 
[72,73,108]. In all these guidelines the following validation parameters are 
fundamental: linearity and range, sensitivity (LOD and LOQ), accuracy, precision, 
specificity and recovery. 
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3.3.1.1 Linearity and Range 
 
The linearity of the signal response is determined by preparing a calibration curve 
within a given (therapeutic) range and is expressed by the regression coefficient. 
In this work, the calibration curve was constructed with six different analyte 
concentrations. The stock solution of the model analyte Cyclosporine A (100 µg/mL) 
was prepared in DMSO. This solution was added to a drug free EDTA blood sample 
in order to obtain a 1000 ng/mL solution. This spiked blood sample was further 
diluted with the original blood sample to obtain the remaining calibration standards: 
500, 200, 80, 40 and 10 ng/mL. 10 µL of the Internal Standard solution (10 µg/mL of 
D12-CyA in DMSO) was added to 490 µL of the calibration standard samples. The 
drug free EDTA blood sample was used as matrix blank sample.  
The calibration curve was constructed from double runs. The peak area ratios of the 
analyte to the IS were plotted against the concentration of the analyte.  
The calibration curve shown in Figure 42 proved to be linear over the range of 10 
ng/mL to 1000 ng/mL. The regression coefficient for the calibration curve was 0.990. 
 
 
Figure 42: Calibration curve for Cyclosporine A in 20 µL of processed whole blood, i.e. CDB. 
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3.3.1.2 Sensitivity 
 
The sensitivity of an analytical method is determined by measuring the limit of 
detection (LOD) and the lower limit of quantitation (LLOQ). The LOD is the lowest 
analyte concentration that can be distinguished from noise. The signal to noise ratio 
(S/N) of the analyte peak must be at least 3:1. The LLOQ is defined as the lowest 
analyte concentration that can be determined quantitatively. The analyte signal must 
be at least five times higher when compared to a blank sample.   
The LOD values were found to be 3.3 ng/mL for CyA in 20 µL of anticoagulated 
whole blood sample. The LLOQ turned out to be 10 ng/mL.  
 
 
3.3.1.3 Accuracy and Precision 
 
The accuracy is a measure of the closeness of mean test results obtained by the 
method to the true concentration of the analyte. The accuracy is calculated using the 
following equation: 
 (Equation 5) 
It is recommended to measure the accuracy using a minimum of five replicate 
samples at each concentration level of the quality control (QC), namely low, mid and 
high level. 
The precision is the closeness of agreement (degree of scatter around the mean) 
between a series of individual measurements obtained from multiple sampling of the 
same sample. Precision is expressed as percentage of the relative standard 
deviation (%RSD) of the replicate analyses. It is recommended to measure the 
precision using a minimum of five replicate samples at each concentration level of the 
quality control (QC), namely low, mid and high level. Precision in this work was 
further investigated with respect to intra-day and inter-day variations. The inter-day 
assay was carried out using daily-prepared QC samples and calibration curve.  
The intra- and inter-day accuracy and precision were determined from QC samples 
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prepared by spiking CyA into a whole blood sample at a concentration of 800 ng/mL 
and serially diluting the spiked sample with the original whole blood sample to 400 
ng/mL and 25 ng/mL. 
Table 2 and Table 3 document the data obtained for intra- and inter-day accuracy 
and precision respectively. The intra-day accuracy ranges from 0.12 to 13.6 %, and 
the intra-day precision ranges from 4.07 to 7.01 %RSD. The average values of all the 
three concentration levels from two consecutive runs on two separate days are within 
15% of the expected concentration. The inter-day precision ranges from 3.8 to 9.04 
%RSD. 
 
 
Table 2: Determination of intra-day accuracy and precision at 3 different concentration levels of 
Cyclosporine A in 20 µL of processed whole blood, i.e. CDB. 
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Table 3: Determination of inter-day accuracy and precision at 3 different concentration levels of 
Cyclosporine A in 20 µL of processed whole blood, i.e. CDB. 
 
 
 
3.3.1.4 Recovery 
 
The recovery is an assessment of how efficient the extraction and the overall analysis 
procedure are. In this work, recovery was further investigated with respect to matrix-
dependent and matrix-independent recovery.  
Matrix-dependent recovery was measured by comparing the on-line SPE-LC-MS/MS 
analysis of a spiked blood sample with the spiked EtOH solution.   
Comparison of on-line analysis with off-line analysis of a solution of the analyte 
dissolved in EtOH yields the matrix-independent recovery. Off-line analysis of this 
solution was achieved by direct injection of the sample onto the analytical column. 
For the calculation of the recovery the mean value of the resulting concentrations 
was assumed to be 100%.  
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These two recoveries are calculated using the following equations: 
 (Equation 6) 
 (Equation 7) 
 
As shown in Table 4, the matrix-dependent recovery values ranges from 80.9% to 
94.3% with standard deviation from 7.0% to 17.2%. In addition, the spiked neat 
solutions were analyzed off-line as well, and the corresponding matrix-independent 
recoveries are presented in Table 5.  
 
 
Table 4: Matrix-dependent recovery of Cyclosporine A at 3 different concentrations in 20 µL of 
processed whole blood, i.e. CDB. 
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Table 5: Matrix-independent recovery of Cyclosporine A at 3 different concentrations in 20 µL 
of processed whole blood, i.e. CDB. 
 
 
 
3.3.2 Determination and improvement of the robustness of the total 
analysis platform 
 
3.3.2.1 Determination of the robustness of individual subunits of the platform 
 
In order to determine the robustness of the developed analysis method, each 
individual subunit of the original platform was tested with regard to its robustness. 
The test involved the injection needle of the sample handling/injection unit, the 
heated capillary of the processing unit (heat-shock treatment), the in-line filter sieve 
and the TurboFlow SPE column of the clean-up unit, the guard column and the 
analytical column of the separation unit.  
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For the test, the analysis cycle (see 3.2.6) of 20 µl anticoagulated whole blood 
sample with a HCT value of 0.45 was repeated so many times until the system back 
pressure exceeded its limit (550 bar). After figuring out and exchanging the part 
which caused the high back pressure, the analysis cycle was continued until the next 
high back pressure built up again. 
The results of the robustness test for the individual units are documented in the 
following: 
The injection needle was not clogged after 400 injections of each of 20 µL whole 
blood.  
The heated stainless-steel capillary (300 x 0.5mm ID) did not develop a back 
pressure after 400 injections of each of 20 µL whole blood. This result compares 
quite well with the one reported by Berger [15].  
During the repeated processing and analysis of whole blood, a layer of matrix 
proteins (Biofilm) is built up on the inside of all tubings, which are in contact with the 
biofluid, especially the heated capillary. Thus, it is recommended to clean injection 
needle and all tubings with BCA-reagent after 200 injections of each of 20 µL whole 
blood, in order to get rid of the biofilm. Otherwise, there might be a carryover or 
memory effect. 
The sieve of the in-line single sieve builts up a back pressure of more than 550 bar 
after 185 injections of each 20 µL of processed whole blood, i.e. CDB. In another run, 
215 injections of each of 20 µL CDB did not cause any significant raise in back 
pressure. 
The back pressure of the TurboFlow SPE column (Cyclone-P, 50 x 0.5 mm ID) raised 
to about 400 bar after 220 injections of each of 20 µL whole blood, i.e. CDB. 
The analytical column (Accucore PFP, 50 x 2.1 mm ID) developed a back pressure of 
more than 550 bar after 220 injections each of 20 µL of processed whole blood, i.e. 
CDB.  
The build-up of a high back pressure by the in-line single sieve filter, by the 
TurboFlow SPE column and by the analytical column, point to an insufficient clean-up 
of the matrix. Thus, the overall analysis procedure was further optimized (see below) 
in order to achieve at least 500 consecutive injections without the need to exchange 
any hardware.  
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3.3.2.2 Improvement of the robustness of the total analysis platform 
 
The robustness of the total analysis system was improved by changing operational 
parameters, composition of mobile phases and hardware. 
 
Step 1: Varying the fractionation volume  
The build-up of back pressure in the columns was most probably caused by matrix 
components remaining in the SPE column after the fractionation step. This residual 
matrix then is denatured during the transfer step using 100 % MeOH and clog both 
SPE and analytical column. In order to confirm this, 20 µL of heat-shock treated 
whole blood (CDB) samples were fractionated using different volumes of mobile 
phase (H2O/ACN, 95/5, v/v). The back pressure of the SPE column (coupled with the 
in-line single sieve filter) was monitored during the repeating injections as shown in 
Figure 43. New SPE column and in-line single sieve filter were used for each new 
fractionation series. A home-made test SPE column (40 x 1 mm ID) packed with 
Oasis HLB material (dp 10 µm) was used. This SPE column was comparable with the 
TurboFlow SPE column (Cyclone-P, 50 x 0.5 mm ID). 
From Figure 43 it is obvious that the fractionation volume for 20 µL of a CDB sample 
using a mobile phase of H2O/ACN (95/5, v/v) at 2 mL/min should be at least 5 mL 
(169 times of dead volume of the SPE column).  
The TurboFlow SPE (TFC) column has a smaller ID and thus a higher linear flow 
velocity at 2 mL/min. Thus the flow rate for fractionation on the Oasis HLB SPE 
column was enhanced to 5 mL/min (the maximum of the available HPLC pump) in 
order to get a linear flow velocity comparable with the TFC column.  
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Figure 43: Back pressure of Oasis HLB SPE column (40 x 1mm ID) and in-line single sieve filter 
after repeated injection of heat-shock treated whole blood (20 µL) and fractionation 
with varying volumes of mobile phase (H2O/ACN, 95/5, v/v). 
 
Step 2: Varying the amount of organic modifier in mobile phases for fractionation- 
and transfer 
The rise in back pressure also could be caused by partial denaturation of the blood 
protein matrix during the heat-shock treatment and during the transfer step due to the 
presence of an organic modifier. In this context, it should be noted that 2 to 5 vol% of 
ACN are required to displace target analyte(s) from their protein binding sites prior to 
Solid Phase Extraction (SPE). 
As a reference sample, Cryo CDB prepared from the same whole blood sample by 
off-line cryogenic treatment was used. 
Figure 44 depicts the resulting profiles of the back pressure. It is obvious that 
enhancing the amount of organic modifier (in this case acetonitrile) does not have a 
significant effect. This also holds when raising the amount of methanol from 50% to 
100% in the transfer step.  
The repeated injection of the reference sample (off-line snap-frozen whole blood, 
cryo CDB) did not cause any significant rise in back pressure, even after 50 
injections.   
From these findings it is obvious that the mobile phases used for the fractionation 
and transfer step have no significant influence in the built-up of back pressure. On 
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the other hand, the heat-shock treatment seems to generate larger 
particles/agglutinates compared to the cryogenic treatment of whole blood. These 
larger particles/agglutinates finally clog the sieve of the in-line filter and/or the SPE 
column. 
 
Figure 44: Back pressure of Oasis HLB SPE column (40 x 1mm ID) and in-line single sieve filter 
after repeated fractionation and transfer elution of heat-shock treated and snap-
frozen whole blood samples (20 µL) using varying amounts of organic modifier. 
 
Step 3: Varying the conditions for heat-shock treatment 
As mentioned in 3.2.2, the in-line processing of anticoagulated whole blood by heat-
shock treatment and the corresponding basic processing parameters (tmin, tmax, theat) 
have been described by Milojković [16]. For a mixture of whole blood and IS in 2.5 
vol% DMSO, the optimal heating time is 13 seconds at 75 °C. The minimum heating 
time at 75 °C is 9 seconds, and 30 seconds at 70 °C .  
In order to see if the processing parameters influence the generation of larger 
particles/agglutinates, the absolute heating time at 75 °C and 70 °C was varied.  
Figure 45 shows the resulting profiles of the rise in back pressure of the SPE column 
and the in-line single sieve filter during repetitive fractionation steps.  
It is obvious that the reduction of the processing time from 13 seconds to 9 seconds 
at 75 °C does not have any significant effect on th e rise of the back pressure. The 
same holds true for reducing the processing temperature from 75 °C to 70 °C.  
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Figure 45: Back pressure of Oasis HLB SPE column (40 x 1mm ID) and in-line single sieve filter 
after repeated fractionation of snap-frozen and heat-shock treated whole blood 
samples (20 µL) applying varying conditions. 
 
Step 4: Finding optimal hardware for in-line filter 
In order to optimize the in-line filtration step two devices were compared. 
The first one was a filter housing containing a woven three-layered metal sieve with 
smallest mesh size of 1 µm. This dead-volume free device is called in-line single 
sieve filter (see also 3.2.3).  
The second one was a cartridge with varying length and inner diameter (in-line 
packed depth filter). The filter cartridge was dry packed with different porous 
materials, which possess electro-neutral and hydrophilic properties. The packing 
materials also varied in particle size 5-60 µm and pore size 60-120 nm. The purpose 
of the second filter device was to act as a depth filter for retaining cell nuclei and “cell 
debris” generated during the heat-shock treatment.  
The profiles of the back pressure of the SPE column and the two different filters are 
shown in Figure 46.  
Back pressure builds up much slower when using the depth filter instead of the single 
sieve filter.  
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Figure 46: Back pressure of Oasis HLB SPE column (40 x 1mm ID) and filter (in-line single 
sieve filter or in-line depth filter) after repeated fractionation of snap-frozen and heat-
shock treated whole blood (20 µL). 
 
In a next step the inner diameter of the depth filter was extended from 2 to 4 mm. 
During the repeated injections of processed whole blood samples, i.e. CDB, the back 
pressure of the system was monitored at two different time points in the overall 
analysis cycle. 
One was the back pressure generated by both, the SPE column and the in-line depth 
filter after the fractionation step. The other one was the back pressure of the depth 
filter during back flushing. From the profiles shown in Figure 47 it follows that the 
back pressure built up much slower in both cases when using a depth filter with a 
larger inner diameter.  
 
Figure 47: Back pressure of Oasis HLB SPE column (40 x 1mm ID) and/or depth filter (with 
different ID) after fractionation of in-line heat-shock treated whole blood samples (20 
µL) and/or during back-flushing. 
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Finally, depth filter (5 x 4mm ID) packed with different modified silica materials 
(spherical silica, broken silica and large pore silica) were compared. The back 
pressure of the SPE column and depth filter was monitored during repeated 
injections (Figure 48). The depth filter packed with spherical silica particles provided 
the best results and was used for further studies.  
 
Figure 48: Back pressure of Oasis HLB SPE column (40 x 1mm ID) and depth filter packed with 
different modified silica materials (5 x 4mm ID) after fractionation of in-line heat-
shock treated whole blood (20 µL). 
 
Step 5: Finding optimal cleaning conditions for in-line depth-filter and SPE column  
Another option to reduce the back pressure during repeated operation is to wash the 
depth filter and the SPE column properly in order to remove any residual matrix 
components. For this purpose, the system configuration was modified accordingly in 
order to wash the depth filter and the SPE column separately (see Figure 53).  
15 % Acetic acid was used to remove acid-soluble proteins. A mixture of organic 
solvents was used to remove hydrophobic matrix components, such as lipids.   
Figure 49 depicts the resulting profiles of the back pressure of the depth filter and the 
SPE column when using different wash programs. It is obvious that cleaning the 
depth filter with 15% acetic acid and the SPE column with 15% acetic acid as well as 
with a mixture of organic solvents gives the best result. The rise in back pressure is 
even less compared with the reference sample being repeatedly injected onto an in-
line single sieve filter.  
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Figure 49: Effect of different wash programs on back pressure of Oasis HLB SPE column (40 x 
1mm ID) and depth filter (5x4 and 10x4mm ID, packed with spherical, modified silica) 
after fractionation step of in-line heat-shock treated whole blood (20 µL). 
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Step 6: Determination of the robustness of the total analysis platform using the 
optimized in-line depth filter hard ware and wash program  
The robustness of the total analysis platform was evaluated using the optimized hard 
ware (in-line depth filter), a larger fractionation volume (4.2 mL, corresponding to 430 
times of the dead volume of the TFC SPE-column) and the optimal wash program 
(wash in-line depth filter with 15% acetic acid, wash TFC SPE-column with 15% 
acetic acid and a mixture of organic solvents).  
 
 
 
Figure 50: Monitoring of the back pressure of clean-up and separation unit during repeated 
analysis of in-line processed whole blood sample (CDB, 10 µL) under optimized 
conditions. 
 
The robustness of the total analysis platform finally was significant improved as can 
be seen from the pressure profiles shown in Figure 50: 
The on-line clean-up system composed of the in-line depth filter (10 x 4 mm ID) 
packed with spherical, modified silica and the TurboFlow SPE column Cyclone-P (50 
x 0.5 mm ID) built up a back pressure of less than 31 bar after 500 injections each of 
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10 µL of whole blood. The in-line depth filter contributed to a rise in back pressure of 
only 3-4 bar during 200 consecutive injections.  
The separation system (guard column and analytical column, Hypersil Gold PFP 10 x 
2.1 mm and 50 x 2.1 mm ID) built up a back pressure of 21 bar after 500 injections 
each of 10 µL of whole blood. The guard column contributed to back pressure of 
about 17 bar.   
 
 
Figure 51: Monitoring of MS/MS response of direct analysis of in-line heat-shock treated whole 
blood sample (10 µL) using TFC-LC system. 
 
In addition, the MS/MS responses of the analyte (Cyclosporine A) and the IS 
(Cyclosporine D) were monitored during the repeated analysis cycles, as shown in 
Figure 51. The RSD value for 500 injections counts to 15.6% for Cyclosporine A, and 
15.2% for Cyclosporine D. 
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3.4 Description and evaluation of the improved, final total 
analysis platform for quantitation of Cyclosporine A 
after heat-shock treatment of whole blood 
 
After the optimization of the hard ware and packing material as well as wash program 
for the in-line depth filter, a final overall analysis cycle has been composed (see 
Figure 52). This final total analysis platform for the detection and quantitation of 
Cyclosporine A after heat-shock treatment of whole blood has been evaluated with 
respect to the following: 
- Validation parameters 
- Robustness   
- Comparison with an established, LC-MS/MS method for routine analysis of 
patient samples 
- Applicability of commercial calibrators and quality control samples (ClinCal 
and ClinCheck from Recipe)  
 
 
3.4.1 Final overall analysis cycle 
 
The final overall analysis cycle – which relies on an in-line depth filter packed with 
spherical, modified silica and an optimal wash program– for the direct determination 
of Cyclosporine A in an anticoagulated whole blood sample (10 µL) lasts 14.4 min.  
This is documented in the representative chromatogram (Figure 52), where individual 
steps of the overall analysis cycle are color coded.  
The detailed instrumental set-up for the analysis steps 4 – 9 is displayed in Figure 53. 
The mobile phases used in each step of the overall analysis cycle are listed in Table 
6.  
The software Chronos allows a time optimization of sequential analysis. The second 
analysis starts during the separation step of the analyte(s). Thus the duration for the 
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second analysis cycle as well as for the following cycles amounts to 10.9 minutes 
each (Step 4-9). 
 
 
Figure 52: Final overall analysis cycle for fully automated quantitation of Cyclosporine A in 
whole blood. 
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Figure 53: Final system configuration for in-line processing of a whole blood sample by heat-
shock treatment and on-line SPE-LC-MS/MS analysis of the processed sample 
(CDB): Analysis cycle steps 4-9. 
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Table 6: Time table of final overall analysis cycle: Flow rates, compositions of mobile phases 
and functions of pump settings. 
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3.4.2 Validation of the improved, final method 
 
As the experimental conditions, i.e. hard ware, packing material and wash program of 
in-line depth filter for the improved method (see also 3.3.2.2) have been changed, a 
new validation was required. The validation parameters are described in 3.3.1, and 
the results are presented in the following. 
 
 
3.4.2.1 Linearity and Range 
 
A new calibration curve was constructed with seven different analyte concentrations 
in the rage of 10 to 1000 ng/mL.  
The calibration curve shown in Figure 54 proved to be linear over the tested 
concentration range. The regression coefficient for the calibration curve was 0.9977. 
 
 
Figure 54: Calibration curve for Cyclosporine A in 10 µL whole blood using the final analysis 
protocol. 
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3.4.2.2 Sensitivity 
 
The LOD value was found to be 5.4 ng/mL for CyA in 10 µL of anticoagulated whole 
blood sample. The LLOQ turned out to be 10 ng/mL.  
 
 
3.4.2.3 Accuracy and Precision 
 
Table 7 and Table 8 document the data obtained for intra- and inter-day accuracy 
and precision respectively. The intra-day accuracy ranges from 0.06 to 7.93 %, and 
the intra-day precision ranges from 2.68 to 4.53 %RSD. The average values of all 
three concentration levels from three consecutive runs on three separate days are 
within 15 % of the expected concentration. The inter-day precision ranges from 3.46 
to 4.96 %RSD. 
 
 
Table 7: Determination of intra-day accuracy and precision at 3 different concentration levels of 
Cyclosporine A in 10 µL of whole blood using the final analysis protocol. 
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Table 8: Determination of inter-day accuracy and precision at 3 different concentration levels of 
Cyclosporine A in 10 µL of whole blood using the final analysis protocol. 
 
 
3.4.2.4 Recovery 
 
The matrix-independent recovery was only measured for the middle level (200 
ng/mL) of Cyclosporine A solved in EtOH. The EtOH standard solution was analyzed 
in triplicate. The matrix-independent recovery was 98.2 % with standard deviation of 
4.1 %. The matrix-dependent recovery value ranges from 100.5 % to 106.1 % with 
standard deviation from 1.8% to 4.3%, as shown in Table 9. It is obviously that the 
matrix-dependent recovery was significantly improved by optimization of the in-line 
filter hard ware, packing material and wash program. 
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Table 9: Mean values and standard deviations for matrix-dependent recovery of Cyclosporine A 
at 3 different concentrations in 10 µL of whole blood using the final analysis protocol. 
 
 
3.4.3 Robustness of the improved, final total analysis platform  
 
As documented in chapter 3.3.2.2 (step 6), the robustness of the improved total 
analysis platform was significantly improved by optimization of the hard ware, 
packing material and wash program for the in-line depth filter: 
The on-line clean-up system composed of the in-line depth filter (10 x 4 mm ID) 
packed with spherical, modified silica and the TurboFlow SPE column Cyclone-P (50 
x 0.5 mm ID) built up a back pressure of 31 bar after 500 injections each of 10 µL of 
whole blood. The in-line depth filter contributed to a rise in back pressure of only 3-4 
bar during 200 consecutive injections.  
The separation system (guard column and analytical column, Hypersil Gold PFP 10 x 
2.1 mm and 50 x 2.1 mm ID) built up a back pressure of 21 bar after 500 injections 
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each of 10 µL of whole blood. The guard column contributed to a back pressure of 17 
bar.   
In addition, the MS/MS responses for the analyte (Cyclosporine A) and the IS 
(Cyclosporine D) were monitored during the 500 analysis cycles. The relative 
standard deviation (RSD) of 500 injections of each of 10 µL of whole blood amounts 
to 15.6 % for Cyclosporine A, and 15.2 % for Cyclosporine D. 
 
 
  
95 
 
3.4.4 Applicability of commercial calibrators and quality control 
samples  
 
The optimized total analysis platform was further evaluated with regard to the use of 
commercial available calibrators and quality control samples. The lyophilized 
calibrator ClinCal from RECIPE Chemicals + Instruments GmbH was used to 
construct the calibration curve. The lyophilized quality control samples ClinCheck 
(low, middle and high level) were used for internal quality assurance. In this context, 
it was found that the protein matrix of the lyophilized samples precipitates upon 
heating. Therefore, these samples were treated at room temperature.  
The calibration curve was constructed from double runs with six different analyte 
concentrations and the blank sample of the ClinCal kit. The calibration curve shown 
in Figure 55 proved to be linear over the range of 0 ng/mL to 1264 ng/mL. The 
regression coefficient for the calibration curve is 0.9996. 
 
 
Figure 55: Calibration curve for Cyclosporine A in 10 µL ClinCal samples using the final 
analysis protocol. 
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The intra-day accuracy and precision were determined from triple analysis of 
ClinCheck samples, which are available in three different levels of concentration of 
Cyclosporine A. 
As shown in Table 10 the intra-day accuracy ranges from 1.11 to 14.53 %, and the 
intra-day precision ranges from 3.57 to 4.64 % RSD.  
 
 
Table 10: Determination of intra-day accuracy and precision at 3 different concentration levels 
of Cyclosporine A in 10 µL of ClinCheck sample applying the final analysis protocol 
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3.4.5 Comparison with an established method for routine analysis 
of patient samples 
 
The final total analysis platform was compared with the established method of the 
Institute of Laboratory Medicine, Medical Center of the University of Munich, for 
routine LC-MS/MS analysis of Cyclosporine A in patient samples. As a matter of 
routine, the whole blood samples of patients treated with Cyclosporine A were off-line 
(i.e. manually) precipitated prior to on-line SPE-LC-MS/MS analysis. The results of 
the routine method were used as reference values. After having been stored at 4 °C 
for at least 3 days, the same patient samples were in-line heat-shock and/or off-line 
cryogenic treated prior to on-line SPE-LC-MS/MS analysis as described in the final 
protocol (see 3.4.1).  
 
The inter-laboratory method comparison is based on Passing and Bablok plots. 
Figure 56 shows the comparison of SPE-LC-MS/MS determination of Cyclosporine A 
in 42 patient blood samples, after off-line protein precipitation and in-line heat-shock 
treatment, respectively. The equation for the Passing and Bablok regression line is Y 
= 1.0857 X – 18.8158. The 95 % confidence interval (CI) for the slope is from 1.0188 
to 1.1885. This small proportional difference indicates a good agreement between 
both methods. The 95 % confidence interval (CI) for the intercept is from -34.7705 to 
-10.4387. This constant difference indicates an average abatement of the measured 
concentration of in-line heat shock treated blood samples of patients. In general, the 
Passing and Bablok regression analysis shows a very good agreement of the two 
methods compared. 
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A.  
B.  
Figure 56: Inter-laboratory method comparison (Passing and Bablok regression analysis), n=42 
SPE-LC-MS/MS-determination of Cyclosporine A in off-line protein precipitated and 
in-line heat shock treated blood samples of patients. 
A. Scatter diagram with regression line and confidence bands for regression line 
B. Residual plot of distribution of difference around fitted regression line 
  
Figure 57 shows the comparison of SPE-LC-MS/MS determination of Cyclosporine A 
in 17 patient blood samples, after off-line protein precipitation and off-line snap-
freezing, respectively. The equation for the Passing and Bablok regression line is Y = 
0.997 X – 1.5111. The 95 % confidence interval (CI) for the slope is from 0.8330 to -
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1.2631. The 95 % confidence interval (CI) for the intercept is from -29.0592 to 
13.7629. In general, the Passing and Bablok regression analysis shows again a very 
good agreement of the two different methods compared. 
 
A.  
B.  
Figure 57: Inter-laboratory method comparison (Passing and Bablok regression analysis),n=17. 
SPE-LC-MS/MS-determination of Cyclosporine A in off-line protein precipitated and 
off-line snap-frozen (cryo CDB) blood samples of patients. 
A. Scatter diagram with regression line and confidence bands for regression line 
B. Residual plot of distribution of difference around fitted regression line 
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Figure 58 shows the comparison of SPE-LC-MS/MS determination of Cyclosporine A 
in the 17 patient blood samples, after in-line heat shock treatment and off-line snap 
freezing, respectively. The equation for the Passing and Bablok regression line is Y = 
0.9158 X + 12.1846. The 95 % confidence interval (CI) for the slope is from 0.7137 to 
1.0722. The 95 % confidence interval (CI) for the intercept is from -3.6691 to 
32.9425. In general, the Passing and Bablok regression analysis shows a very good 
agreement of the two methods compared. 
 
A.  
B.  
Figure 58: Method comparison (Passing and Bablok regression analysis), n=17. SPE-LC-
MS/MS-determination of Cyclosporine A in in-line heat shock treated (in-line CDB) 
and off-line snap-frozen (cryo CDB) blood samples of patients. 
A) Scatter diagram with regression line and confidence bands for regression line 
B) Residual plot of distribution of difference around fitted regression line 
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In addition, 25 patient samples have been in-line heat-shock treated and on-line 
analyzed using SPE-LS-MS/MS on three consecutive days. The inter-day accuracy 
and precision of the measured patient samples are shown in Table 11.  
The inter-day accuracy ranges from 0.22 to 28.51 %, and the inter-day precision 
ranges from 2.45 to 15.55 % RSD. The average values of all the patient samples 
from three consecutive runs on three separate days are within 15 % of the expected 
concentration, except one patient sample 31-2717.  
 
Table 11: Determination of inter-day accuracy and precision of Cyclosporine A measurement in 
10 µL of whole blood of patients using the final analysis protocol 
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3.4.6 Evaluation and elimination of matrix effects 
 
The matrix effects on the ionization response of the analytes were tested by two 
different approaches:  
1) Comparison of the absolute MS peak area(s) of the analyte(s) obtained from 
spiked matrix samples, i.e. whole blood and spiked neat samples, i.e. EtOH. The 
samples were spiked with the same concentration of analyte(s) and underwent the 
same processing and SPE-LC-MS/MS analysis procedures.  
2) Post-column infusion of a solution of the analyte into the eluent of LC introduced to 
the ion source. After reaching a steady baseline, i.e. ionization, a blank matrix sample 
is injected, heat-shock treated, fractionated and separated. Any matrix components 
of the sample which affects the ionization process, causes either a decline of the 
baseline, i.e. ion suppression, or a raise of the baseline, i.e. ion enhancement.  
The result of the first approach is documented in a plot of the peak area versus the 
concentration of the analyte for spiked matrix samples and spiked neat samples 
(Figure 59). 
 
 
Figure 59: Evaluation of matrix effects: Comparison of the MS peak area of the analyte 
Cyclosporine A obtained from spiked matrix samples and spiked neat samples. 
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The difference in the peak areas at the same concentration is due to a matrix effect. 
In this case the ionization of Cyclosporine A is suppressed.  
The extend of matrix effects can be given in percent and is calculated according to 
Equation 1. The calculation of the matrix effects at each of the different 
concentrations revealed a value of about minus 25%. 
Inter-individual matrix effects have been monitored by measuring blood samples from 
seven healthy people. All these blood samples were spiked with Cyclosporine A to a 
concentration of 500 ng/mL. As reference, a spiked neat sample of EtOH with a 
concentration of 500 ng/mL was used. The results for inter-individual matrix effects 
are listed in Table 12. The magnitude of matrix effects in 7 different blood samples is 
around minus 22%. This means that the matrix effects are independent from the 
concentration of the analyte and are similar in individual samples.  
 
 
Table 12: Monitoring of inter-individual matrix effects by measuring 7 different blood samples 
spiked with 500 ng/mL Cyclosporine A 
 
Figure 60 shows the post-column infusion LC-MS/MS chromatograms of both, blank 
matrix sample (processed whole blood, i.e. CDB) and blank neat sample (EtOH). 
Both chromatograms are overlayed with a chromatogram obtained after injection of a 
solution of Cyclosporine A in EtOH.  
The peaks at 4.5 min in both infusion chromatograms are due to valve switching for 
transfer step. The peaks at 10 min are due to valve switching for separation step. The 
fluctuation of the baseline during the transfer step (4.5 - 10 min) is due to the varying 
composition of the mobile phase and/or coeluting matrix components. The varying 
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composition of the mobile phase also contributes to the rise of the baseline during 
the separation step in post-column infusion chromatogram of blank neat sample 
(EtOH). Compared to that, no rise of the baseline during the separation step in the 
post-column infusion chromatogram of the blank matrix sample (CDB) was observed. 
This indicates that ion suppression is caused by the sample matrix.  
 
 
Figure 60: Evaluation of matrix effects: Post-column infusion (PCI) LC-MS/MS chromatograms 
of blank matrix sample (processed whole blood, i.e. CDB), blank neat sample (EtOH) 
and a regular chromatogram of Cyclosporine A in EtOH.   
 
In order to eliminate the observed matrix effect, the wash program for on-line SPE-LC 
has been partially optimized, as described in 3.3.2.2. An optimal wash program could 
be achieved using an additional pump channel. A mixture of H2O/ACN (75/25, v/v) 
could be used to flush the in-line depth filter and SPE column at the end of 
fractionation step. However, this could not be performed in our method because our 
HPLC pump does not have such an additional channel for the additional wash 
solvent. 
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3.5 Development of a SPE-LC-MS/MS method for analysis 
of Cyclosporine A using in-line cryogenic treatment of 
whole blood 
 
The SPE-LC-MS/MS based analysis method for in-line snap-frozen whole blood (cryo 
CDB) was exactly the same as described in 3.4.1. Two additional steps, however, 
had to be optimized, namely the sampling of the blood sample by a special 
processing needle and the snap-freezing/thawing process.  
 
 
3.5.1 Optimization and standardization of sampling of whole blood 
for cryogenic treatment 
 
After mixing of a sedimented blood sample (cf. 3.2.1.1), an aliquot (up to 40 µL) of 
homogenized blood sample is aspirated into the processing needle. The processing 
needle has a relative large inner diameter and thus the syringe speed was set to       
2 µL/s in order to aspirate reproducible blood volumes.  
During the freezing process the sample volume expands. Therefore, the blood 
sample is air-segmented in such a way, that it is positioned in the center of the 
stainless steel processing needle. This ensures that no sample is lost during the 
freezing process. The optimal aspiration and segmentation sequence turned out to 
be:  
20 µL air gap (pre sample) – 40 µL whole blood – 30 µL air gap (post sample). 
It was found, that due to the large inner diameter, residual wash solution remained in 
the lumen of the processing needle. Therefore, the processing needle was dried with 
a nitrogen stream at the end of the wash step.    
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3.5.2 Optimization of in-line processing of whole blood by cryogenic 
treatment 
 
A sample of 40 µL of anticoagulated whole blood was in-line processed under 
different conditions with respect to freezing rate, freezing time, warming rate and 
thawing time. The resulting cryo CDB samples were examined by light microscopy. 
All the produced cryo CDB samples were mixed with Trypan Blue (1:100), and 
inspected at a magnification of one thousand. Under optimal conditions for in-line 
cryogenic treatment, no intact erythrocytes could be detected.  
It turned out that the optimal processing parameters for in-line cryogenic treatment of 
whole blood (40 µL) are as follows:    
Freezing rate:       1296 °C/min 
Freezing time:       10 s 
Warming rate:       200 °C/min 
Thawing time:        60 s 
 
In addition, it could be shown that these process parameters are independent of 
both, the hematocrit and the blood species.  
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4. Discussion 
 
Prerequisites for an optimal LC-MS/MS method for clinical-chemical / 
pharmacological quantitation of small molecules, e.g. drugs and endogenous 
compounds in body fluids are, that such a procedure  
- should have a short analysis time 
- should be selective and sensitive  
- should be robust 
- should not be disturbed by ion suppression when applying an ESI-mode in 
MS/MS detection 
- should be fully automated and thus allow the direct injection and integrated 
processing of the body fluid investigated.  
 
In this context, it has been shown recently that anticoagulated whole blood can be 
converted into so-called Cell-Disintegrated Blood (CDB). CDB represents a 
homogenous blood matrix which can be further pretreated and analyzed using any 
combination of high performance liquid fractionation, separation and detection 
systems [17]. 
One procedure for such a system-integrated, i.e. in-line conversion has been 
described, namely the heat-shock treatment [15,16]. With regard to a second 
procedure, i.e. the cryogenic treatment of whole blood, only preliminary results have 
been published [109]. 
A major aim of this thesis was to implement both procedures into an autosampler and 
hyphenate them with an on-line SPE-MS/MS system. 
For this purpose, a dedicated XYZ– autosampler was configured in cooperation with 
LEAP Technologies (Carrboro, NC, USA) and Axel Semrau GmbH (Sprockhövel, 
Germany). 
This special autosampler was programmed to mix a sedimented whole blood sample 
in a vortexer. The two liquid handling / injection units implemented in the platform 
were programmed to aspirate a blood sample and / or an Internal Standard, thereby 
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segmenting both by, e.g. an air gap. After sampling of whole blood, the injection 
needle can be washed from outside using a pump-driven wash module in order to 
remove any contamination. The newly developed DLW module of CTC Analytics AG 
(Zwingen, Schweiz) / LEAP Technologies (Carrboro, NC, USA) was found to be a 
unique liquid handling system, as it can aspirate and dispense highly viscous 
samples such as whole blood. As shown, this device guarantees a highly 
reproducible and contamination-free injection of whole blood. This is because that 
the fluid to be analyzed is aspirated not into the lumen of a conventional stainless-
steel injection needle or syringe body, but into the lumen of a sample holding loop 
made of Tygon. In combination with the optimized air / liquid / sample segmentation, 
as well as wash programs, a near-zero carryover / memory effect could be achieved. 
After aliquoting, the blood sample is processed in-line in two ways and converted into 
a homogeneous matrix, i.e. Cell-Disintegrated Blood (CDB), by heat-shock treatment 
for 13 seconds at 75 °C or by snap-freezing with li quid nitrogen followed by slow 
thawing.   
The heat-shock treatment takes place in a heated stainless-steel HPLC capillary (300 
x 0.5 mm ID), which is directly connected to the injection valve. This is achieved by 
using a heated sleeve (250 x 1.587 mm ID) instead of a column oven. This 
configuration minimizes the dead volume between the injection port and the heated 
capillary. Combined with an optimal segmentation of the blood sample in the holding 
loop of the injection needle, a dilution of the blood sample and thus a lysis of blood 
cells by the aqueous mobile phase are also minimized.  
The cryogenic treatment could be optimized with regard to sample volume, sample 
segmentation, freezing rate, freezing time, warming rate and warming time. The 
optimal processing parameters for in-line cryogenic treatment of a 40 µL air 
segmented whole blood sample turned out to be 10 seconds for freezing by contact 
with liquid nitrogen and 60 seconds for thawing at room temperature.  
 
It was found that for on-line SPE-LC-MS/MS analysis of processed whole blood, i.e. 
CDB, a replaceable in-line filter has to be inserted between the sample inlet and SPE 
column in order to prevent clogging of capillaries, sieves and columns by cell nuclei 
and “cell debris”.  
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In this work, two different in-line filters were investigated. The single sieve filter 
consists of a special three-layered stainless-steel sieve in a dead volume free 
housing. The filter device is sealed by a Teflon ring and a conical pressure screw. 
Because of the small pore diameter of the sieve (approximately 1 µm), all the 
components and agglomerates larger than 1 µm formed during the in-line processing, 
especially during the heat-shock treatment of blood samples, could be withheld by 
this in-line filter. Sample components of smaller size, however, were retained by the 
serial connected SPE column and then transferred to the analytical column. This 
caused a rise in back pressure of both SPE and analytical column after 220 injections 
/ processing cycles each of 20 µL whole blood. 
Therefore, the filter device was optimized by converting it into a depth filter.  Different 
porous packing materials, which possess electro-neutral and hydrophilic properties, 
were tested in depth filters of varying length and inner diameter. We discovered that 
spherical hydrophilic silica is the material of choice for retaining cell nuclei and “cell 
debris” generated during the heat-shock treatment. In addition, the conditions for 
forward and backward flush of the filter after fractionation of the blood sample and 
transfer of the analyte(s) could be optimized.  
For a rapid and effective sample clean-up, i.e. depletion of the macromolecular 
sample matrix, a TurboFlow SPE column (Cyclone-P, 50 x 0.5 mm ID) was 
investigated. Due to the high linear flow velocity during operation and the resulting 
very short residence time of the sample in the column, macromolecular sample 
components have no time to diffuse into the pores and thus are eluted very 
effectively in the void volume to waste.  
The installed configuration of the switching valves and tubings allows that the 
TurboFlow SPE column can be back flushed separately from the in-line depth filter 
after fractionation of the CDB sample and transfer of the analyte(s). By this measure, 
the life-time of both the depth filter and the SPE column could be extended 
significantly.  
The described heat-shock treatment of a blood sample requires a relatively low flow 
rate of the sample and mobile phase, respectively. On the other hand, the SPE-
based fractionation of the processed sample, i.e. CDB, requires a relatively high flow 
rate. To solve this problem, a holding loop with a volume of 200 µL was inserted 
between the outlet of the heated capillary and the TurboFlow SPE column. This 
110 
 
allowed the heat-shock treatment of the blood sample to proceed at a flow rate of 
270 µL/min and the operation of the SPE column at a flow rate of 2000 µL/min. 
The final total analysis platform for quantitation of the model analyte Cyclosporine A 
after heat-shock treatment of anticoagulated whole blood was evaluated with regards 
to different aspects.  
First, the developed method was validated. It was shown that the method is linear in 
the range of 10 (LLOQ) to 1000 ng/mL. The intra-day and inter-day accuracy and 
precision are within the limits required by the FDA for a bioanalytical method. A 
matrix-independent and a matrix-dependent recovery of around 100% demonstrate 
that the on-line SPE-step is very efficient. By comparing the MS-response of the 
model analyte Cyclosporine A in a spiked sample of whole blood with a sample of 
Cyclosporine A dissolved in EtOH with the same concentration, it was shown that the 
ionization process is suppressed by approximately 25 %. However, the addition of an 
Internal Standard, i.e. Cyclosporine D, can totally compensate for these matrix 
effects.  
The robustness of the total analysis platform could be optimized by improving the 
hardware for the in-line filter and the wash programs for the in-line filter and the SPE 
column. After 500 injections each of 10 µL of whole blood, the on-line clean-up 
system (composed of the in-line packed depth filter and the TurboFlow SPE column) 
built up a back pressure of 31 bar, and the separation system (guard column and 
analytical column) built up 21 bar. Furthermore, the MS/MS responses for the analyte 
(Cyclosporine A) and the Internal Standard (Cyclosporine D) were monitored during 
500 analysis cycles. The relative standard deviation (RSD) of 500 injections amounts 
to 15.6 % for Cyclosporine A and 15.2 % for Cyclosporine D. These findings prove 
that this analysis platform is robust and thus can be used in routine. 
The optimized analysis method was further evaluated by an inter-laboratory method 
comparison. The routine method established in the Institute of Laboratory Medicine, 
Medical Center of the University of Munich, was used as a reference. It relies on a 
manually performed precipitation of a whole blood sample prior to on-line SPE-LC-
MS/MS analysis of the resulting supernatant obtained after centrifugation. A method 
comparison applying Passing and Bablok plots shows very good agreement between 
the described method and an established routine method controlled by proficiency 
test. The measured concentrations of Cyclosporine A in heat-shock treated patient 
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samples (n = 42) are slightly lower than those routinely determined. One possible 
reason for this might be that the same patient samples have been measured after at 
least three days storage at 4 °C, while in the rout ine laboratory the patient samples 
are analyzed on the first day. Compared to heat-shock treated samples, snap-frozen 
samples revealed a smaller difference. However, fewer samples have been analyzed 
after cryogenic treatment (n = 17). Therefore, it is difficult to estimate which 
processing method is better from a statistical point of view. In addition, the inter-day 
accuracy and precision of 25 heat-shock treated patient samples has been 
determined. The average values of all 25 patient samples (with only one exception) 
from three consecutive runs on three separate days are within 15 % of the reference 
concentration measured in routine. 
Finally, the applicability of commercial calibrators (ClinCal, Recipe, Munich) and 
quality control samples (ClinCheck, Recipe, Munich) was tested. The protein matrix 
of these lyophilized samples turned out to precipitate upon heating. Processing these 
samples at room temperature, however, solved this problem. Also, a very good 
linearity ranging from 0 to 1264 ng/mL for the model analyte Cyclosporine A as well 
as very good accuracy and precision were found.  
 
In conclusion, the described SPE-LC-MS/MS platform fulfills the criteria needed in 
clinical-chemical analysis as it 
- has a short total analysis time (< 11minutes)  
- is selective and sensitive with a LLOQ of 10 ng/mL for the model analyte 
Cyclosporine A  
- is robust and tolerates at least 500 injections each of 10 µL of whole blood  
- is slightly affected by ion suppression. These matrix effects, however, can 
be totally compensated for by addition of the Internal Standard 
Cyclosporine D 
- is comparable with an established, semi-automated method in routine use 
- is fully automated and allows for the direct injection and integrated 
processing of anticoagulated whole blood samples. 
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5. Summary 
 
The thesis describes the configuration, optimization and evaluation of a novel 
instrumental platform for fully automated SPE-LC-MS/MS analysis of small 
molecules, such as drugs, in whole blood.  
The immunosuppressant Cyclosporine A was chosen as a model analyte, as this 
drug is predominantly bound to erythrocytes. 
First, anticoagulated blood is converted into so-called Cell-Disintegrated Blood (CDB) 
by heat-shock or cryogenic treatment. CDB represents a homogenous blood sample 
and consists of subcellular particles which do not sediment on standing and do not 
clog capillaries, sieves or HPLC column packings.  
For in-line treatment of anticoagulated whole blood, i.e. generation of CDB, a sample 
mixing unit, two special liquid handling units and two home-made sample processing 
modules were embedded into a XYZ-autosampler. 
The module for heat-shock treatment consists of a stainless-steel capillary jacketed 
with a heating sleeve. Under optimal conditions for sampling and in-line processing of 
20 µL of whole blood, it takes 13 seconds at 75 °C to generate CDB. The latter is 
stored in a holding loop before further treatment.  
For cryogenic treatment of a blood sample, a stainless-steel processing needle with a 
large inner diameter was installed in one of the liquid handling units. The 
autosampler was programmed to introduce the processing needle containing the 
blood sample (40 µL) into a stand-pipe, which is located in a thermo-flask filled with 
liquid nitrogen. The processing needle therefore contacts liquid nitrogen and the 
blood sample is snap-frozen. Optimal conditions were found to be 10 seconds for 
snap-freezing at -196 °C and 60 seconds for thawing  at room temperature.  
A CDB sample obtained either by heat-shock or cryogenic treatment is further 
processed by being pumped via a switching-valve through an in-line filter to retain 
cell nuclei and “cell debris”. It was found that a depth filter packed with spherical 
hydrophilic silica is optimal. This filter allows at least 200 analysis cycles before it has 
to be replaced.  
Next, the CDB sample is pumped on-line via another switching-valve through a SPE 
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column (50 x 0.5 mm ID) at a high flow rate. Due to the special packing material and 
the very small inner diameter, a high linear flow velocity is achieved and turbulent 
flow is generated. By this, high-molecular matrix components such as proteins are 
eluted in the void volume to waste. The low-molecular weight target analyte 
Cyclosporine A and the Internal Standard Cyclosporine D are retained and extracted 
by reversed phase partitioning chromatography (RPC). 
After fractionation of CDB on the SPE column, the analyte and the IS are transferred 
to a series-connected analytical column and separated from residual matrix 
components by RPC. Finally, the analyte is detected by a tandem mass spectrometer 
applying electrospray ionization (ESI) and multiple reaction monitoring (MRM).  
The optimized method has a total analysis time of less than 11 minutes. The 
analytical procedure and the instrumental platform were validated for heat-shock 
treated blood samples with respect to linearity, range (10 - 1000 ng/mL), lower limit of 
quantitation (10 ng/mL), intra-day and inter-day accuracy and precision, as well as 
matrix-independent and matrix-dependent recovery (around 100 %). It was shown 
that the electrospray induced ionization is suppressed by approximately 25 %. These 
matrix effects, however, can be totally compensated for by the addition of an Internal 
Standard, i.e. Cyclosporine D.  
A comparison with a semi-automated SPE-LC-MS/MS method, established in the 
Institute, revealed a very good agreement. This was shown by Passing and Bablok 
plots.   
The robustness of the fully automated SPE-LC-MS/MS analysis platform was 
monitored during 500 consecutive analysis cycles with heat-shock treated blood 
samples. The relative standard deviation for the signal response was 15.6 % for 
Cyclosporine A and 15.2 % for Cyclosporine D. The back pressure of the total system 
rose only by 52 bar.  
These findings show that, despite its instrumental and chromatographic complexity, 
the described analysis platform fulfills the prerequisites to be used in routine clinical-
chemical analysis.  
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6. Zusammenfassung 
 
Die Doktorarbeit beschreibt die Konfiguration, Optimierung und Evaluierung einer 
neuartigen instrumentellen Plattform für die vollständig automatisierte SPE-LC-
MS/MS Analyse von kleinen Molekülen, wie beispielsweise Arzneistoffe, im Vollblut.  
Das Immunsuppressivum Cyclosporin A wurde als Modellanalyt gewählt, da dieser 
Arzneistoff vorwiegend an Erythrozyten gebunden ist.  
Zunächst wird antikoaguliertes Blut durch eine Hitze- oder Kälteschock Behandlung 
in sogenanntes Zell-desintegriertes Blut (Cell-Disintegrated Blood, CDB) überführt. 
CDB stellt eine homogene Blutprobe dar und besteht aus subzellulären Partikel, die 
beim Stehen nicht sedimentieren und keine Kapillaren, Siebe und HPLC- 
Packungsmaterialien verstopfen.  
Für die in-line Behandlung von antikoagulierten Vollblut, d.h. für die Herstellung von 
CDB, wurde ein Gerät zum Mischen der Probe, zwei spezielle Bauteile für die 
Handhabung von Flüssigkeiten und zwei selbst-gebaute Module für die 
Probenprozessierung  in einen XYZ-Probengeber eingebaut.  
Das Modul für die Hitze-Schock Behandlung besteht aus einer Edelstahlkapillare, die 
mit einer Heizmanschette ummantelt ist. Unter optimalen Bedingungen für die 
Probenahme und in-line Prozessierung von 20 µL Vollblut werden 13 Sekunden und 
75 °C benötigt um CDB herzustellen. Letzteres wird vor einer weiteren Behandlung in 
einer Rückhalteschleife gelagert. 
Für die Tieftemperatur Behandlung einer Blutprobe wurde eine weitlumige 
Edelstahlnadel zur Prozessierung in eines der Bauteile für die Handhabung von 
Flüssigkeiten eingebaut. Der Probengeber wurde so programmiert, dass die Nadel, 
welche die Blutprobe (40 µL) enthält, in ein Steigrohr, welches sich in einem mit 
flüssigem Stickstoff gefüllten Isolierbehälter befindet, eingeführt wird.  
Hierdurch wird die Nadel mit flüssigem Stickstoff kontaktiert und die Blutprobe 
schockgefroren. Als optimale Bedingungen wurden 10 Sekunden für das 
Schockgefrieren bei -196 °C und 60 Sekunden für das  Auftauen bei Raumtemperatur 
gefunden.  
Eine CDB Probe, die entweder durch Hitze- oder Kälteschock-Behandlung 
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gewonnen wurde, wird weiter prozessiert, indem sie über ein Schaltventil durch einen 
in-line Filter gepumpt wird, um Zellkerne und „Zellbruchstücke“ zurückzuhalten. Es 
stellte sich heraus, dass ein Tiefenfilter, der mit sphärischem hydrophilem Kieselgel 
gepackt ist, optimal ist. Dieser Filter ermöglicht mindestens 200  Analysen-Zyklen 
bevor er ausgetauscht werden muss.    
In einem weiteren Schritt wird die CDB Probe on-line über ein weiteres Schaltventil 
mit einer hohen Flussrate durch eine SPE Säule (50 x 0.5 mm ID) gepumpt. 
Aufgrund des speziellen Packungsmaterials und dem sehr kleinen Innendurchmesser 
wird eine hohe lineare Flussgeschwindigkeit erreicht und eine turbulente Strömung 
erzeugt. Hierdurch werden hochmolekulare Matrixkomponenten wie beispielsweise 
Proteine im Totvolumen in den Abfall eluiert. Niedermolekulare Zielanalyte wie 
Cyclosporin A und der interne Standard Cyclosporin D werden über Umkehrphasen- 
Verteilungschromatographie (RPC) reteniert und extrahiert.  
Nach der Fraktionierung von CDB auf der SPE Säule, wird der Analyt und der interne 
Standard auf eine in Serie geschaltete analytische Säule überführt und von restlichen 
Matrixbestandteilen über RPC abgetrennt. Zum Schluss wird der Analyt in einem 
Tandem-Massenspektrometer über eine Elektrospray Ionisation (ESI) und Multiple 
Reaction Monitoring (MRM) detektiert.  
Die optimierte Methode weist eine Gesamtanalysezeit von weniger als 11 Minuten 
auf.  
Das Analysenverfahren und die instrumentelle Plattform wurden für Hitzeschock 
behandelte Blutproben hinsichtlich Linearität, Messbereich (10 – 1000 ng/mL), 
unterer Bestimmungsgrenze (10 ng/mL), Richtigkeit und Präzision innerhalb eines 
Tages und von Tag zu Tag, sowie Matrix-unabhängiger und Matrix-abhängiger 
Wiederfindung (um 100 %) validiert. Es konnte gezeigt werden, dass die über 
Elektrospray induzierte Ionisation um ca. 25 % unterdrückt wird. Diese Matrixeffekte 
können jedoch durch Zugabe des internen Standards Cyclosporin D vollständig 
kompensiert werden.  
Ein Vergleich mit einer teilautomatisierten SPE-LC-MS/MS Routinemethode, die im 
Institut etabliert ist, ergab eine sehr gute Übereinstimmung. Dies konnte anhand von 
Passing und Bablok Plots aufgezeigt werden. 
Die Robustheit der vollständig automatisierten SPE-LC-MS/MS Analysenplattform 
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wurde während 500 aufeinander folgenden Analysezyklen mit Hitzeschock 
behandelten Blutproben überprüft. Die relative Standardabweichung für das MS-
signal betrug 15.6 % für Cyclosporin A und 15.2 % für Cyclosporin D. Der Rückdruck 
des gesamten Systems stieg nur um 52 bar an.  
Diese Ergebnisse zeigen, dass – trotz der instrumentellen und chromatographischen 
Komplexität – die beschriebene Analysenplattform die Anforderungen, die in der 
klinisch-chemischen Routineanalytik gestellt werden, erfüllt.   
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7. Appendix 
 
7.1 Equipment and Materials 
 
SPE-LC-MS/MS (-UV): 
 
Autosampler CTC Analytics (CTC Analytics, Zwingen, CH) 
HPLC pumps Agilent Technologies 1100 Series (Agilent, Santa Clara, CA, 
USA) 
Merk-Hitachi L 6200 intelligent pump (Merck KGaA, Darmstadt, 
Germany) 
Degasser Agilent Technologies 1100 Series (Agilent, Santa Clara, CA, 
USA) 
Column oven HotDog 5090 (Prolab GmbH, Reinach, CH) 
Capillary heater MultiSLEEVE and AgileSLEEVE Plus (Analytical Sales and 
Services, Inc., NJ, USA) 
Mass Spectrometer Quattro Micro TM (Waters, Manchester, UK) 
LTQ Velos (ThermoFisher Scientific, USA) 
UV-Detector Agilent Technologies 1100 Series (Agilent, Santa Clara, CA, 
USA) 
Software Chronos (Axel Semrau GmbH & Co. KG, Sprockhövel, 
Germany) 
ChemStation Rev.B.04.03 (Agilent, Santa Clara, CA, USA ) 
MassLynx 4.1 (Waters Corporation, Milford, USA) 
Xcalibur (ThermoFisher Scientific, USA) 
In-line Filter (Recipe Chemicals + Instruments GmbH, Munich, Germany) 
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SPE columns 
 
Cyclone-P  50 x 0.5 mm ID, ThermoFisher Scientific, USA 
Home-made column 40 x 1 mm ID, packed with Oasis HLB material (dp 10 µm, 
Waters Corporation, Milford, USA) 
  
Analytical columns 
 
Accucore PFP 50 x 2.1mm ID, ThermoFisher Scientific, USA 
Hypersil Gold PFP 10 x 2.1 mm and 50 x 2.1 mm ID, ThermoFisher Scientific, USA 
  
Other Equipment 
 
Centrifuge 5415 D Eppendorff AG, Hamburg, Germany 
Balance Sartorius CP 
225 D-OCE  
Sartorius AG, Göttingen, Germany 
pH-meter Metrohm 691 Deutsche Metrohm GmbH & Co.KG, Filderstadt, Germany 
Microscope Olympus Deutschland GmbH, Hamburg, Germany 
Ultrasonic Bath Bandelin electronic GmbH Co. KG, Berlin, Germany 
Sieves Haver & Boecker OHG, Oelde, Germany 
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7.2 Chemicals and Reagents 
 
Cyclosporine A Novartis International, Basel, CH 
Cyclosporine D Novartis International, Basel, CH 
Cyclosporine A – D12 Novartis International, Basel, CH 
Clin Cal ® RECIPE Chemicals + Instruments GmbH, Munich, 
Germany 
Clin Check ® RECIPE Chemicals + Instruments GmbH, Munich, 
Germany 
Dimethyl Sulfoxide Sigma-Aldrich, Steinheim, Germany 
Acetonitrile J. T. Baker, Deventer, Netherlands 
Ethanol J. T. Baker, Deventer, Netherlands 
Methanol J. T. Baker, Deventer, Netherlands 
Water J. T. Baker, Deventer, Netherlands 
Formic Acid  Merck KGaA, Darmstadt, Germany 
Ammonium Acetate Sigma-Aldrich, Steinheim, Germany 
Sodium Chloride Merck KGaA, Darmstadt, Germany 
Acetic Acid Merck KGaA, Darmstadt, Germany 
BCA™ Protein Assay Thermo Scientific, Rockford, IL, USA 
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